Titan Pharmaceuticals 2 - 500 Beiträge pro Seite

[Erbse1]

Hallo liebe TTP Fans.
Ich habe einen neuen Thread zu Titan eröffnet, da der alte doch ziemlich lang geworden ist.
Bisher hats viel Spaß gemacht, Titan zu beobachten.
Ich bitte Euch die Diskussion in diesem Thread weiterzuführen.
Liebe Grüße
Erbse1

[boriz]

tja, gibt es denn nichts zu titan ? ausser dass ich sie inzwischen schon 20% biliger bekommen hätte ?

bORiZ

[puhvogel]

Momentan macht Biotechinvesting geneell wenig Spass. Außer den ganz großen Biotechs werden die kleinen von der NASDAQ-Schwäche überproportional mitgerissen, und TTP gehört dazu.
Wirklich gute Nachrihten werden glattweg ignoriert.
Ein Problem können auch Verkäufe zur steuerlichen Realisierung von Verlusten werden.

[boriz]

Aktie im Blickpunkt: Titan Pharmaceuticals (TTP, WKN: 914404) Das auf ZNS-Erkrankungen spezialisierte
Unternehmen gab gestern seine Quartalszahlen bekannt. Die Umsätze für das 2.Quartal beliefen sich auf 2,9
Mio. USD verglichen mit 281.000 USD im Vorjahreszeitraum. Die Umsätze für das Halbjahr stiegen auf 3,5
Mio. USD in 2001 verglichen mit 616.000 USD im Jahr 2000. Dieser enorme Anstieg der Umsätze wurde vor
allem durch die Lizenzzahlungen des Kooperationspartners Novartis (NOVN VX; WKN: 904278) für die
Entwicklung und Vermarktung des Medikamentes Zomaril (Iloperidone) in Japan begründet. Titan konnte zum
Ende dieses Quartals über Finanzreserven in Höhe von 113,1 Mio. USD berichten. Der Nettoverlust im
2.Quartal lag bei 1,8 Mio. USD oder 7 Cents pro Aktie, verglichen mit 2,4 Mio. USD oder 9 Cents pro Aktie im
Vorjahreszeitraum. Damit konnten die durchschnittlichen Markterwartungen, die sich auf 15 Cents pro Aktie
beliefen eindeutig geschlagen werden- Für die ersten sechs Monate des laufenden Jahres betrug der
Nettoverlust 6,4 Mio. USD oder 23 Cents pro Aktie verglichen mit einem Nettoverlust von 6,1 Mio. USD oder 24
Cents pro Aktie im Vergleichszeitraum des Vorjahres. In einem Conference Call wies Titan auf viel
versprechende Entwicklungen hin, die dem Unternehmen bald zu gute kommen sollen: Die erfolgte Phase III
Anmeldung des Medi-kamentes CeaVac, das zur Behandlung von Darmkrebs eingesetzt werden soll; ferner
erfreuliche Forschungsergebnisse hinsichtlich des potenziellen Parkinson-Medikamentes Spheramine aus
der klinischen Phase I/II und die Erweiterung des Lizenzabkommens mit Novartis zur Entwicklung von Zomaril
in Japan. Nach diesen positiv stimmenden Zahlen bzw. Ausblick bestätigen wir erneut unser „Kaufen“-Rating
für Titan Pharmaceuticals (Stopp-Loss: 10 USD). Nähere Angaben zu den besprochenen Werten, sowie
weitere Brancheninformationen finden Sie in dem monatlich erscheinenden Biotechnologie-Börsenbrief
Hornblower BioStrategy, Probeexemplar anfordern unter: www.hornblower.de/biostrategy/index.phtml
Hornblower Fischer AG Börsenstraße 2-4 60313 Frankfurt www.hornblower.de

[boriz]

@all

nachkaufen ? meinungen ?

[Erbse1]

Hallo liebe TTP Fans. Hab hier noch eine kleine Empfehlung gefunden. TTP tut sich wirklich im Augenblick sehr schwer. Mich wundert das aber nicht besonders, wenn selbst bei diesen Kursen Aktien vom Vorstand auf den Markt geworfen werden. Folgend noch kurz die Empfehlung
Liebe Grüße Erbse1
------------------------------------------------------------
04.09.2001
Titan Pharmaceuticals kaufen
Hornblower Fischer

Die Analysten von Hornblower Fischer stufen die Aktien von Titan Pharmaceuticals (WKN 914404) mit kaufen ein.

Die Aktie sei am 30. August durch den von den Experten gesetzten Stopp-Loss bei 10 US-Dollar gefallen und notiere aktuell bei 9,75 US-Dollar. Dieser Rückschlag sei marktbedingt gewesen und sei nicht durch negative Unternehmensnachrichten ausgelöst worden. Negativ sei allerdings anzumerken, dass Titan nicht von der 3-Tages-Rallye des Amex Biotechnology Index vom 22. – 24. August (+13,2%) habe profitieren können.

Man denke aber, dass Investoren sich im derzeitigen nervösen Markt bei einer Reaktion nach oben zuerst auf die Schwergewichte der Branche stürzen und vielversprechende, aber auch risikoreichere Werte aus der zweiten Reihe erst in ruhigeren Börsenphasen ins Depot legen würden.

Die Börsenkenner von Hornblower Fischer bestätigen erneut ihr fundamentales Kaufen-Rating, wobei ein Stopp-Loss bei 8 US-Dollar gesetzt werden sollte.


------------------------------------------------------------

[puhvogel]

@boriz: Man muss sich leider bei den aktuell billigen Kursen vergegenwärtigen, dass dies Jahr noch Verkäufe aus steuerlichen Gründen kommen müssten. Auch die amis müssen Spekusteuer zahlen und können sie gegen Verluste gegenrechnen.

[boriz]

@puhvogel

hi,
aber wieso bist du dir so sicher dass die jetzt kommen ? ich meine man kann doch nicht wissen wann die gekauft haben..oder verpeil ich was ?
naja, heute ging es 8% hoch, so dass ich mir mal wieder in den arsch beisse nicht nachgekauft zu haben. immer das selbe, ich kaufe eine aktie und dann fällt sie erstmal so 10-20%, ich traue mich nicht nachzukaufen, und dann steigt sie wieder auf den einstandskurs und das spiel beginnt von vorne

[puhvogel]

Nein sicher bin ich über-überhaupt nicht, aber bei manchen Werten sieht man solche Muster vor Jahresende deutlich, speziell bei ehemaligen Lieblingen, die noch von Shorts nach unten gedrückt werden. KDE und Macrochem sind solche Beispiele. Es beträfe auch keineswegs nur Titan sondern auch andere.
Solches 10% Herumgezuppel ist doch fast alltäglich. wichtig ist, dass man dabei ist, wenn sich solche Werte wie CVTX Anfang 2000 auf den Weg machen

[boriz]

oh gott, unter 10, hoffentlich kracht titan jetzt nicht durch die stops !

boriz

[Erbse1]

Hallo Boriz. Nur keine Panik. Der Kurs wird in Amerika gemacht. Auf den Kurs in Deutschland kannst du nichts geben.
Hier in Deutschland wird manchmal ein Aufschlag von fast 10% gezahlt. Mich wundert immer wieder, wer da kauft. Andersrum wird manchmal bis zu 10% Abschlag zum amerikanischen Kurs verkauft.Wenn du Titan verfolgen willst gib doch bei Comdirect einfach TTP ein und richte Dich nicht nach dem deutschen Kurs.
Liebe Grüße Erbse1

[boriz]

@erbse

mich juckt es nachzukaufen. aber bei dem markt macht das keinen spass .. habe vor ca 6 wochen genentech, titan und vertex gekauft ---> 16% minus gesamt. und darauf habe ich keinen bock aber panik kriege ich nicht ! ich bleibe in diesen werten, basta !

boriz

[erkilein]

habe mich hier noch nicht gemeldet, aber wo die interessantesten dinger besprochen werden, treffe ich immer wieder puhvogel, komisch
die kaufphase beginnt langsam, die ersten TTP´s werde ich zum doppelten des cashwertes reinnehmen, also bei 180-200 mio marcetcap (ca 6-7 $), dort dürfte dann ein guter ansatz gefunden werden, wie sich aus dem mauerblümchen-thread mittlerweile gezeigt hat. bei etwas weniger als 4 $ liegt der cashwert. aber man kann sich beim sammeln wohl zeit lassen, denn die kleineren werden erst später in die depots genommen als vertex zB. ich hoffe, ihr habt alle noch genügend cash um langsam aber sicher zuzugreifen, aber noch nicht im hightechbereich. aber nebenwerte, die steigende gewinne machen und unter 10er kgv notieren, gehören jetzt gekauft. lass mal bei die hightechs neue zahlen kommen und die 2003er kgv´s sind dann schon wieder bei 60. das ist noch lange nicht ausgestanden, 2002 gehört auch noch zur depressionsphase bei den meisten "bekannten" aktien. 7-8 Jahre dauert ein konjunkturzyklus und das, seit es dieses wort gibt, 1870 glaub ich.

[erkilein]

opa und eltern sagen: Vergiß nicht die 3 "K´s"- Konjunktur, Krise, Krieg:O

[Erbse1]

Hallo liebe TTP Fans. Ich möchte mal kurz die Insidertrades des letzten Jahres hier reinkopieren. Da soll noch einer Vertrauen in die Zukunft von Titan haben. Außer das Zomaril um ca. ein Jahr verschoben ist ist ja gar nichts passiert. Doch selbst bei den jetzigen Kursen wird vom Vorstand verkauft. Meines Erachtens ist der Kursabschlag vollkommen übertrieben. Machts mal gut und liebe Grüße Erbse1.
------------------------------------------------------------
23-Aug-01 KASH, PETER M
Shareholder 8,709
TTP Proposed Sale (Form 144).
Estimated proceeds of $100,154.
20-Aug-01 SMITH, LEY S
Director * 10,000
TTP Purchased at $10.80/Share.
Cost of $108,010.
6-Aug-01 FARRELL, ROBERT E
Chief Financial Officer 2,000
TTP Proposed Sale (Form 144).
Estimated proceeds of $24,480.
2-Aug-01 FARRELL, ROBERT E
Chief Financial Officer,Officer 2,000
TTP Sold at $12.24/Share.
Proceeds of $24,480.
31-Jul-01 FARRELL, ROBERT E
Chief Financial Officer,Officer 31,200
TTP Sold at $11.71 -- $12.31/Share.
Proceeds of $377,350.
30-Jul-01 FARRELL, ROBERT E
Chief Financial Officer,Officer 40,000
TTP Sold at $11.88/Share.
Proceeds of $475,360.
26-Jul-01 FARRELL, ROBERT E
Other Executive 37,865
TTP Proposed Sale (Form 144).
Estimated proceeds of $467,632.
25-Jul-01 FARRELL, ROBERT E
Trust, Trustee 40,000
TTP Proposed Sale (Form 144).
Estimated proceeds of $493,600.
25-Jul-01 FARRELL, ROBERT E
Trust, Trustee 31,000
TTP Proposed Sale (Form 144).
Estimated proceeds of $370,450.
19-Jun-01 HUCKEL, HUBERT E
Director * 3,000
TTP Purchased at $27.40 -- $27.50/Share.
Cost of $82,240.
4-Jun-01 BHONSLE, SUNIL RAMRAJE
Executive Vice President, Chief Operating Officer * 100,000
TTP Sold
31-May-01 BHONSLE, SUNIL RAMRAJE
Executive Vice President, Chief Operating Officer 100,000
TTP Proposed Sale (Form 144).
Estimated proceeds of $3,390,000.
17-May-01 BAUER, VICTOR
Director 5,000
TTP Gave as Gift.
Value of $171,050.
4-Apr-01 CAVALIER, EURELIO M
Director 5,000
TTP Acquired Shares via Exercise of Options at $2.47/Share.
Paper gain of $84,400 at a fair market value of $19.35/share on 4-Apr-01.
28-Mar-01 FARRELL, ROBERT E
Chief Financial Officer 6,000
TTP Sold at $24.05/Share.
Proceeds of $144,300.
27-Mar-01 FARRELL, ROBERT E
Chief Financial Officer 16,000
TTP Sold at $22.34 -- $22.68/Share.
Proceeds of $359,480.
23-Mar-01 FARRELL, ROBERT E
Chief Financial Officer 16,000
TTP Proposed Sale (Form 144).
Estimated proceeds of $303,930.
22-Mar-01 BHONSLE, SUNIL RAMRAJE
Executive Vice President, Chief Operating Officer 45,081
TTP Acquired Shares via Exercise of Options at $7.13 -- $7.50/Share.
Paper gain of $531,438 at a fair market value of $19.00/share on 22-Mar-01.
22-Mar-01 FARRELL, ROBERT E
Chief Financial Officer 13,500
TTP Sold at $18.70 -- $19.18/Share.
Proceeds of $257,305.
16-Mar-01 BAUER, VICTOR
Director 5,000
TTP Acquired Shares via Exercise of Options at $0.79/Share.
Paper gain of $102,050 at a fair market value of $21.20/share on 16-Mar-01.
15-Mar-01 FARRELL, ROBERT E
Chief Financial Officer 23,848
TTP Surrendered Exercised Shares.
Surrendered Value of $541,588.
15-Mar-01 FARRELL, ROBERT E
Chief Financial Officer 42,013
TTP Acquired Shares via Exercise of Options at $7.50/Share.
Paper gain of $634,816 at a fair market value of $22.61/share on 15-Mar-01.
14-Mar-01 CAVALIER, EURELIO M
Director 5,000
TTP Acquired Shares via Exercise of Options at $2.47/Share.
Paper gain of $101,200 at a fair market value of $22.71/share on 14-Mar-01.
14-Mar-01 FARRELL, ROBERT E
Chief Financial Officer 10,294
TTP Surrendered Exercised Shares.
Surrendered Value of $239,336.
14-Mar-01 FARRELL, ROBERT E
Chief Financial Officer 18,294
TTP Acquired Shares via Exercise of Options at $7.50/Share.
Paper gain of $278,252 at a fair market value of $22.71/share on 14-Mar-01.
9-Mar-01 FARRELL, ROBERT E
Chief Financial Officer 2,425
TTP Surrendered Exercised Shares.
Surrendered Value of $60,625.
9-Mar-01 FARRELL, ROBERT E
Chief Financial Officer 4,425
TTP Acquired Shares via Exercise of Options at $7.50/Share.
Paper gain of $79,562 at a fair market value of $25.48/share on 9-Mar-01.
4-Mar-01 CAVALIER, EURELIO M
Director 10,000
TTP Acquired Shares via Exercise of Options at $3.69/Share.
Paper gain of $252,000 at a fair market value of $28.89/share on 4-Mar-01.
12-Jan-01 ALLEN, RICHARD C
Executive Vice President 75,000
TTP Acquired Shares via Exercise of Options at $0.08/Share.
Paper gain of $1,901,250 at a fair market value of $25.43/share on 12-Jan-01.
12-Jan-01 FARRELL, ROBERT E
Chief Financial Officer 2,029
TTP Surrendered Exercised Shares.
Surrendered Value of $54,986.
12-Jan-01 FARRELL, ROBERT E
Chief Financial Officer 7,329
TTP Acquired Shares via Exercise of Options at $7.50/Share.
Paper gain of $131,409 at a fair market value of $25.43/share on 12-Jan-01.
12-Jan-01 ALLEN, RICHARD C
Executive Vice President 235
TTP Disposed by Private Transaction at $25.40/Share.
Surrendered Value of $5,969.
9-Jan-01 BHONSLE, SUNIL RAMRAJE
Executive Vice President, Chief Operating Officer 115,813
TTP Acquired Shares via Exercise of Options at $1.35/Share.
Paper gain of $2,449,445 at a fair market value of $22.50/share on 9-Jan-01.
8-Jan-01 FARRELL, ROBERT E
Chief Financial Officer 6,608
TTP Surrendered Exercised Shares.
Surrendered Value of $188,328.
8-Jan-01 FARRELL, ROBERT E
Chief Financial Officer 25,108
TTP Acquired Shares via Exercise of Options at $7.50/Share.
Paper gain of $388,672 at a fair market value of $22.98/share on 8-Jan-01.
8-Jan-01 BAUER, VICTOR
Director 4,000
TTP Acquired Shares via Exercise of Options at $3.63/Share.
Paper gain of $77,400 at a fair market value of $22.98/share on 8-Jan-01.
5-Jan-01 FARRELL, ROBERT E
Chief Financial Officer 2,701
TTP Surrendered at $29.80/Share Exercised Shares.
Surrendered Value of $80,490.
5-Jan-01 FARRELL, ROBERT E
Chief Financial Officer 14,900
TTP Acquired Shares via Exercise of Options at $5.30/Share.
Paper gain of $345,680 at a fair market value of $28.50/share on 5-Jan-01.
5-Jan-01 FARRELL, ROBERT E
Chief Financial Officer 201
TTP Acquired Shares via Exercise of Options at $7.50/Share.
Paper gain of $4,221 at a fair market value of $28.50/share on 5-Jan-01.
2-Jan-01 WEIS, KONRAD M
Former, Director 28,112
TTP Gave as Gift.
Value of $871,191.
22-Dec-00 FARRELL, ROBERT E
Chief Financial Officer 8,000
TTP Acquired Shares via Exercise of Options at $5.30/Share.
Paper gain of $223,600 at a fair market value of $33.25/share on 22-Dec-00.
21-Dec-00 BAUER, VICTOR
Director 1,000
TTP Acquired Shares via Exercise of Options at $3.63/Share.
Paper gain of $28,470 at a fair market value of $32.10/share on 21-Dec-00.
6-Dec-00 WEIS, KONRAD M
Former, Director 215
TTP Gave as Gift.
Value of $8,922.
22-Nov-00 FARRELL, ROBERT E
Chief Financial Officer 7,544
TTP Acquired Shares via Exercise of Options at $7.50/Share.
Paper gain of $207,460 at a fair market value of $35.00/share on 22-Nov-00.
4-Oct-00 HUCKEL, HUBERT E
Director 8,300
TTP Sold at $52.03/Share.
Proceeds of $431,849.
3-Oct-00 HUCKEL, HUBERT E
Director 41,800
TTP Sold at $56.25 -- $58.27/Share.
Proceeds of $2,367,006.
3-Oct-00 HEH INVESTMENT PARTNERS LP
Director, Board of Directors 50,100
TTP Proposed Sale (Form 144).
Estimated proceeds of $2,793,075.
25-Sep-00 AFTING, ERNST GUNTER
Director 1,500
TTP Acquired Shares via Exercise of Options at $2.88/Share.
Paper gain of $81,480 at a fair market value of $57.20/share on 25-Sep-00.
25-Sep-00 AFTING, ERNST GUNTER
Director 10,000
TTP Acquired Shares via Exercise of Options at $3.69/Share.
Paper gain of $535,100 at a fair market value of $57.20/share on 25-Sep-00.
25-Sep-00 AFTING, ERNST GUNTER
Director 5,000
TTP Acquired Shares via Exercise of Options at $4.14/Share.
Paper gain of $265,300 at a fair market value of $57.20/share on 25-Sep-00.
25-Sep-00 AFTING, ERNST GUNTER
Director 15,000
TTP Acquired Shares via Exercise of Options at $9.06 -- $9.13/Share.
Paper gain of $721,400 at a fair market value of $57.20/share on 25-Sep-00.
18-Sep-00 FARRELL, ROBERT E
Chief Financial Officer 26,300
TTP Acquired Shares via Exercise of Options at $3.63 -- $3.69/Share.
Paper gain of $998,140 at a fair market value of $41.63/share on 18-Sep-00.
------------------------------------------------------------

[didiprotein]

@boriz
Hallo Boriz!Ich habe am Freitag Titan für ca.6 Euro gekauft.Vor ein paar Wochen hast du mich bei einem Kurs von ca.12 Euro um meine Meinung gefragt und ich sagte auf dem Niveau würde ich nicht kaufen,weil ich nicht sicher bin ob Zomaril ein Blockbuster wird.Nun habe aber auch ich zugeschlagen weil ich glaube daß das Unternehmen in Zukunft große Kurschancen birgt.Ich werde mich auch nicht von der Panik an den Märkten anstecken lassen,sondern investiere langsam in gute Werte!Verkaufen werde ich von meinen Bios nichts.Habe am freitag auch GENOME THERAPEUTICS für 4,70 Euro gekauft!Wenn es nicht gerade zum 3.Weltkrieg kommt werden wir in einem Jahr deutlich höhere Kurse haben!

[thethosch]

Hallo Leute,

ich glaube auch, daß sich gerade jetzt ein Einstieg in Biotechs lohnt, auch gerade in Titan. Antizyklisches Handeln ist jetzt wohl das Beste. Alle haben Angst zu kaufen, aber schon bald wird sich das ändern, und wer jetzt nicht kauft, wird sich in 1-2 Jahren darüber ärgern. Leider bin ich schon voll investiert, sonst würde ich die ganzen Biotech-Perlen jetzt einsammeln.

[boriz]

servus,

und was sagt ihr zu den massiven insiderverkäufen (hi erbse) ??? das zeigt nicht gerade vertrauen. evtl. kriegt man titan bald noch günstiger ?!?! ich habe wieder etwas cash, lasse mir aber zeit. auch weiss ich nicht ob ich nicht mal ein paar dax werte einsammel.

boriz

ps: bin aber noch invewstiert, verkauf kommt nicht in frage...

[Freestyler2001]

Hi @ all!Überlege mir ebenfalls im Moment in Titan einzusteign,nicht nur die Zusammenarbeit mit Novartis reizen sondern auch die gute Pipeline!Jedoch! so sehe ich es zumindest macht der Chart derzeit keinen besonderen Eindruck auf mich,werd Limit setzn,bei ca.5,5$ mal sehn obs funzt.MfG Free

[boriz]

huch, warum der absturz heute ?

boriz

[Erbse1]

Hab hier noch eine offizielle Stellungnahme zu Zomaril gefunden. Ist zwar schon etwas älter und auch Aripiprazole schon ein Jahr auf dem Markt,wenn hier alles glatt läuft. Interessenten die sich für Weiterentwicklungen auf dem Gebiet der Schizophrenie informieren wollen, bitte ich auch mal im Cortexthread vorbeizuschauen.
Liebe Grüße
Erbse1

------------------------------------------------------------
Bisherige Studien bestätigen Sicherheit und Wirksamkeit des in Entwicklung befindlichen neuartigen Präparats
Basel/South San Francisco, 24. Juli 2001 – Titan Pharmaceuticals Inc. und Novartis Pharma AG geben heute bekannt, dass sie Dosierungsstudien planen, um Iloperidon zu einem besseren Profil zu verhelfen. Darin soll unter anderem eine einmal pro Tag zu verabreichende Dosis enthalten sein. Wie die beiden Unternehmen weiter mitteilen, unterstützen die bis heute durchgeführten klinischen Studien das günstige Wirksamkeits-, Sicherheits- und Verträglichkeitsprofil von Iloperidon zur Behandlung akuter Schizophrenie.

Zusätzliche Studien sollen die Verabreichung einmal pro Tag weiter untersuchen, ein vorteilhaftes Sicherheitsprofil beim Wechsel von anderen Antipsychotika zu Iloperidon aufzeigen sowie das kompetitive Profil des Präparats unterstützen. Die Daten aus diesen Studien werden in die ersten Zulassungsgesuche einfliessen. Das erste Gesuch wird in den USA etwa Ende 2002 erwartet, worauf weitere Gesuche an anderen Ländern folgen sollen. Studien für zusätzliche Indikationen, wie die akute Manie, sind ebenfalls geplant.

„In unseren Augen ermöglicht Iloperidon eine bessere Schizophrenie-Behandlung“, sagt Jörg Reinhardt, Leiter Entwicklung Novartis Pharma. „Dabei sehen wir nicht nur das Bedürfnis nach einem wirksamen und gut verträglichen Medikament, sondern auch nach einer einfacheren Dosierung, um die Verabreichung bei dieser Patientenpopulation mit generell schlechter Compliance zu verbessern. Wir finden es deshalb wichtig, eine einmal pro Tag zu verabreichende Dosis zusätzlich in unser Programm aufzunehmen. Unserer Ansicht nach werden die zusätzlichen Studien das klinische Profil von Iloperidon stärken und seine erfolgreiche Überprüfung durch die Zulassungsbehörden in den USA und in Europa vereinfachen“, fügt Jörg Reinhardt hinzu.

Die vor kurzem abgeschlossene Placebo-kontrollierte Studie, Studie 3005, hat zwei Dosierungsbereiche von Iloperidon während sechs Wochen untersucht. Die Ergebnisse aus dem hoch dosierten Bereich (20-24 mg/Tag) zeigten eine statistisch signifikante Verbesserung der Symptome gemäss der 18 Punkte umfassenden Brief Psychiatric Rating Scale (BPRS) und der Positive and Negative Symptom Scale (PANSS) auf. Die Ergebnisse aus dem niedrig dosierten Bereich (12-16 mg/Tag) zeigten statistisch signifikante Ergebnisse für Iloperidon im Vergleich zu Placebo in den Wochen drei, vier und fünf auf, sowie einen numerischen Trend in der Woche sechs. Das günstige Sicherheits- und Verträglichkeitsprofil von Iloperidon wurde in dieser Studie erneut bestätigt. Es beinhaltete ein insgesamt geringes Vorkommen von extrapyramidalen Symptomen (EPS) und Herz-Kreislauf-Effekten, geringe Gewichtszunahmen und eine geringe Sedierung. Solche Nebenwirkungen können die Patienten-Compliance sonst oft beeinflussen.

Die Analyse der Sicherheits- und Wirksamkeitsdaten aus klinischen Versuchen der Phase III, die an mehr als 3`500 Patienten an rund 300 Zentren weltweit durchgeführt wurden, zeigt die Wirksamkeit und das vorteilhafte Sicherheits- und Verträglichkeitsprofil von Iloperidon auf. Insgesamt wurden mit dem Entwicklungsprogramm verschiedenste Dosierungen zwischen 4 und 24 Milligramm pro Tag untersucht.

Die Langzeitdaten aus drei doppelblinden Sicherheitsstudien, die mit rund 1`200 Patienten durchgeführt wurden, zeigen, dass Patienten der Iloperidon-Gruppe in 52 Wochen eine mittlere Gewichtszunahme von nur 1,6–3,7 kg sowie minimale EPS aufwiesen. Letztere blieben stabil oder verbesserten sich gar im Laufe von 52 Wochen. Während 52 Wochen wurden kein erhöhtes Serumprolaktin, keine Anfälle und nur minimale Auswirkungen auf Herzfrequenz und Blutdruck festgestellt.

Novartis hat die Rechte an der Entwicklung, Herstellung und weltweiten Vermarktung von Iloperidon im November 1997 von Titan Pharmaceuticals Inc. in South San Francisco, Kalifornien erworben. „Mehr als 45 Millionen Menschen leiden weltweit an Schizophrenie. Für viele Patienten und Ärzte sind die gegenwärtigen Therapiemöglichkeiten unbefriedigend“, sagt Dr. Louis R. Bucalo, Präsident und CEO von Titan. „Unserer Auffassung nach besitzt Iloperidon klinische Vorteile, die dazu beitragen können, einige der unerfüllten medizinischen Bedürfnisse dieser Patienten zu befriedigen. Wir sind deshalb auch fest entschlossen, ihnen das Medikament so bald wie möglich in der für sie vorteilhaftesten Dosierung zur Verfügung zu stellen.“

Etwa ein Prozent der Weltbevölkerung oder über 45 Millionen Menschen leiden an Schizophrenie. Trotz wichtiger Fortschritte, die in den 1990er Jahren in der Diagnose und Behandlung der Krankheit erzielt wurden, sind die gegenwärtig verfügbaren Psychosebehandlungen für diesen grossen Markt nach wie vor unbefriedigend. Ein allgemeines Problem besteht darin, dass viele Patienten die Behandlung aufgrund unangenehmer oder gefährlicher Nebenwirkungen abbrechen, so etwa wegen Gewichtszunahme, Beeinträchtigung der motorischen Fähigkeiten und Wahrnehmungsstörungen.

Diese Mitteilung enthält in die Zukunft gerichtete Aussagen, die bekannte und unbekannte Risiken, Unsicherheiten und andere Faktoren beinhalten, die zur Folge haben können, dass die tatsächlichen Ergebnisse wesentlich von zukünftigen Ergebnissen, Leistungen oder Errungenschaften abweichen, die in den zukunftsbezogenen Aussagen enthalten oder impliziert sind. Einige der mit diesen Aussagen verbundenen Risiken sind in der englischsprachigen Version dieser Mitteilung und dem jüngsten Dokument „Form 20-F“ der Novartis AG, das bei der US ‚Securities and Exchange Commission‘ hinterlegt wurde, zusammengefasst. Dem Leser wird empfohlen, diese Zusammenfassungen sorgfältig zu lesen.

------------------------------------------------------------

[Erbse1]

Hallo liebe TTP Fans. Novartis plant jetzt noch weitere Tests mit Zomaril. Habe die Meldung erst jetzt gefunden. Das dürfte wohl eine weitere Verschiebung bedeuten. Dann mal wieder in den Keller mit dem Kurs.
Liebe Grüße
Erbse1
------------------------------------------------------------
Novartis plans more trials for schizophrenia drug
BASEL, Switzerland, Oct 11 (Reuters) - Novartis AG plans more clinical trials for schizophrenia drug iloperidone, the Swiss healthcare group said in a statement on Thursday..

``Additional trials are planned for iloperidone to further strengthen its profile in the treatment of schizophrenia,`` Novartis said without elaborating.

Company officials were not immediately available for comment on the drug, whose trade name is Zomaril. Analysts had expected it to be launched in 2003.

------------------------------------------------------------

[boriz]

hab titan mal zu 6,9 nachgekauft....

boriz

[modjo]

bin auch eingestiegen

[erkilein]

ebenso zu 6,85--sollte jetzt ein paar tage streng laufen...oder wenns jeden tag nur en bissl (2-5 %) wird, besteht die chance, dass die aktie in 6 Monaten wieder um die 15 steht. Letzteres wäre mir lieber, anstatt 20 % hoch und runter.

[boriz]

willkommen im club zwischen 6 und 7 war titan die letzte zeit echt immer ein kauf

boriz

[erkilein]

8:27AM Titan Pharm (TTP) 6.03: DB Alex. Brown upgrades to STRONG BUY from Buy; cites highly attractive valuation and strong endorsement and pledge of commitment from partner Novartis (NVS) for anti- psychotic agent Zomaril.

[rjenzi]

Hier die Empfehlung von DB Alex Brown noch ein bisschen ausfuehrlicher:

Harp said that based on new data presented at the Novartis research and development meeting Tuesday, he believes that Zomaril could have ``the best risk-benefit profile of any drug in the current $6 billion class of anti-psychotic agents.``

``Based on our discussions with Novartis senior management, we believe that Novartis AG is fully committed to the rapid clinical development of Zomaril and strongly believes in the product`s excellent profile relative to marketed anti-psychotics,`` Harp said in a research note.

``Importantly, the efficacy and safety data presented at the meeting confirm our belief that Zomaril could achieve sales in excess of $750 million,`` he said, adding Zomaril should belaunched in the fourth quarter of 2004.

``With a technology value of only $54 million and a cash value of over $4 per share, we believe that Titan is significantly undervalued relative to its pipeline of more than five other clinical-stage product candidates and our belief that Zomaril could be a significant product for schizophrenia,`` he said.

Ich hoffe, dass diese Empfehlung nun der Aktie genuegend Kraft gibt, den Abwaertstrend endgueltig zu verlassen!

[boriz]

ich verstehe zwar nicht viel von charttechnik,



aber ich denke der weg bis 10 dürfte auf jedenfall frei sein, oder ?


gruß,

boriz

[KarlPaul]

boriz, scheint auf dem Weg zu sein Derzeit bei 7.90 $, war aber auch schon bei 7,99.

[SieLeiBo]

Titan zeigt heute eine schöne Aufwärtsbewegung.
Viele Tausender-Pakete werden gehandelt.
10day EMA über 20day EMA liegend,
beide ansteigend.
Titan wurde m.E. zu Unrecht verprügelt.

[tommihe]

Nur mal zur Info!

Klinische Entwicklung für pharmazeutische Produkte Titan
Handelsbezeichnung
Partner Anzeigen Aktuelle Phase
CeaVac Pharmazeutische Produkte Titan
keine Krebs Colorectal
III

CeaVac U. TriAb Nationales KrebsInstitut
Pharmazeutische Produkte Titan
Lungenkrebs
II

Iloperidone (Hp873) Pharma AG Novartis
Pharmazeutische Produkte Titan
keine Schizophrenie
III

Pivanex Pharmazeutische Produkte Titan
keine Lungenkrebs
II

Pivanex Pharmazeutische Produkte Titan
keine Tumor (Verschieden)
I/II

RB94 Pharmazeutische Produkte Titan
keine Kopf- u. Ansatzkrebs
Pre-Clinical

Spheramine Pharmazeutische Produkte Titan
Schering AG
Krankheit Parkinsons
I/II

TriAb Pharmazeutische Produkte Titan
keine Brustkrebs
II

TriGem Pharmazeutische Produkte Titan
keine Melanoma
II

Unbekannt Pharmazeutische Produkte Titan
keine Prostatakrebs
Mehrfaches myeloma
II

Zomaril Pharma AG Novartis
Pharmazeutische Produkte Titan
Schizophrenie
III

[SieLeiBo]

Erst steigt die Aktie, dann kommt die (in diesem
Falle positive)Nachricht.
Titan pharm. steigt auch heute wieder deutlich
und hat den Widerstand bei ca. 8$ (seit 10.09.)
deutlich gebrochen. Der Umsatz bis jetzt
entspricht bereits jetzt dem Tagesdurchschnitt.
Die 50day EMA ist in Sicht.
Die Aktie sollte schnell bis erstmal 10$ laufen.
Seht es Euch an!

MfGr SieLeiBo

[Erbse1]

Hier eine Meldung von gestern zu Abilitat, den direkten Konkurenten von Zomaril. So wie es jetzt aussieht ist Abilitat ca 1 Jahr früher auf dem Markt und vom Nebenwirkungsprofil in etwa gleich mit Zomaril. Zu CeaVac tut sich auch große Konkurenz auf. Ich würde bei TTP erst mal zur Vorsicht raten, da die anderen Medikamente sich noch in frühen Stadien befinden.
Liebe Grüße
Erbse1
------------------------------------------------------------
Bristol-Myers Squibb Company (BMY) And Otsuka Pharmaceutical Co., Ltd. Submit New Drug Application For Aripiprazole



PRINCETON, N.J., and TOKYO, Nov. 7 /PRNewswire/ -- Bristol-Myers Squibb Company (NYSE: BMY) and Otsuka Pharmaceutical Company, Ltd. today announced that a New Drug Application (NDA) has been submitted to the U.S. Food and Drug Administration (FDA) for aripiprazole, an investigational novel drug for the treatment of schizophrenia. If approved, aripiprazole will become the first member of the next generation of atypical antipsychotics.

The filing is based on an extensive global clinical development program for aripiprazole, involving numerous controlled trials of up to 52 weeks in duration involving more than 3,000 patients with schizophrenia. In these studies, aripiprazole provided statistically significant improvement of the symptoms of schizophrenia when compared to placebo. In addition, discontinuations due to side effects in patients treated with aripiprazole were not statistically different from discontinuations due to side effects in patients receiving placebo. Based on these data, Bristol-Myers Squibb and Otsuka Pharmaceutical also expect to file applications with additional regulatory authorities to market aripiprazole in countries around the world, including a filing with the European Medicines Evaluation Agency (EMEA) anticipated later this year. Aripiprazole is also being studied for possible utility in other psychiatric disorders, including psychosis in Alzheimer`s disease and bipolar disorder.

"There is a significant unmet medical need for patients suffering from schizophrenia. While currently available antipsychotic drugs help many patients, there is a substantial number of patients who exhibit either partial or inadequate response to therapy or who discontinue their treatment prematurely," said Jeffrey Lieberman, MD, Vice Chairman of Psychiatry, Professor of Psychiatry and Pharmacology, University of North Carolina at Chapel Hill. "One of the main reasons patients discontinue medication is because they feel the side effects are too disabling; therefore, reducing these side effects is crucial to establishing a successful treatment regimen."

Aripiprazole is believed to have a mechanism of action that is fundamentally different from available antipsychotics. Aripiprazole exhibits potent partial agonism of D2 dopamine receptors, associated with partial agonism of 5HT1a serotonin receptors and antagonism of 5HT2 serotonin receptors. Experts believe that regulating the dopamine and serotonin systems is critical to managing the symptoms of schizophrenia and it is hypothesized that the clinical effects of aripiprazole are mediated through its effects on these systems.

"Schizophrenia is one of the most serious and debilitating of mental illnesses," said Richard J. Lane, executive vice president, Bristol-Myers Squibb and president, Worldwide Medicines Group. "It is our hope that aripiprazole will become a significant new treatment choice for physicians, patients and their caregivers, trying to reduce the burden of schizophrenia"

"Otsuka Pharmaceutical is pleased to announce the first regulatory filing for aripiprazole, and we are proud to have discovered this exciting new compound that may become a major therapeutic alternative to help the millions of people suffering from schizophrenia," said Tatsuo Higuchi, president, Otsuka Pharmaceutical. "Together with Bristol-Myers Squibb, we are committed to developing this next generation atypical antipsychotic to its fullest potential."

------------------------------------------------------------

[rjenzi]

Hi Erbse!
Hast Du mehr Informationen zu CeaVac und der Konkurenz Situation? Waere nett, wenn Du Dein Wissen hier reinstellen kannst. Weisst Du wann CeaVac fruehestens auf den Markt kommt und was fuer ein Umsatzpotential CeaVac hat?
Danke schon im Voraus!

[Erbse1]

Hallo liebe TTP Fans. Hier mal was fachliches zu den atypischen Psychosemedikamenten. Bleibt abzuwarten bis auch zu diesem Aspekt Ergebnisse von Abilitat und Zomaril vorliegen. Auf lange Sicht dürfte Zyprexa es schwer haben sich gegen die neuen Medikamente zu behaupten. Dennoch wird es sehr lange dauern bis diese Medikamente einen großen Marktanteil erringen werden. Zyprexa als Marktführer hat 6 Jahre gebraucht, um einen Marktanteil von ca 28% zu erreichen. Bei Risperdal hat es zehn Jahre gedauert einen Anteil von ca 20% zu erreichen.
Wer an neueren Entwicklungen der Psychosemedikamente interessiert ist sollte auch mal im Cortex Thread vorbeischauen. Hier bietet sich die einmalige Chance an einem ganz neuen Lösungsansatz dabei zu sein.
Liebe Grüße
Erbse1
------------------------------------------------------------
Antipsychotic Drugs Tied to Blood Sugar Trouble
By Adam Marcus
HealthScoutNews Reporter
TUESDAY, Nov. 27 (HealthScoutNews) -- New research warns doctors who treat adolescents for schizophrenia and other psychotic illnesses to watch closely for signs of blood sugar trouble.

Scientists have found that a class of widely used antipsychotic medications significantly increases the risk of hyperglycemia, a dangerous surge in blood glucose. The findings, from researchers at Duke University and the Food and Drug Administration (news - web sites) (FDA), appear as a letter in the Nov. 28 issue of the Journal of the American Medical Association (news - web sites).

The research involves a relatively new family of compounds called atypical antipsychotics, which include clozapine and its newer cousin, olanzapine. These drugs have long been known to promote weight gain and increase the risk of diabetes, or fan a smoldering case, although experts don`t know why.

A paper this year in a Journal of Clinical Psychiatry supplement reports the FDA has been alerted to more than 140 cases of new-onset diabetes in patients taking clozapine. Three dozen cases involved ketoacidosis, a potentially deadly complication of elevated blood sugar. The paper also cited 19 case reports of diabetes associated with the use of olanzapine, sold as Zyprexa by Indianapolis-based Eli Lilly and Co.

But the problem hasn`t been studied among patients in adolescence, when symptoms of some psychotic diseases, particularly schizophrenia, usually appear.

In the new research, Dr. Elizabeth Koller, an FDA medical officer, and colleagues culled the agency`s MedWatch database for blood sugar trouble associated with clozapine and olanzapine.

They found 11 reports of runaway blood sugar in patients ages 13 to 18 taking clozapine between January 1993 and March last year. They also found nine reports of similar complications among teens taking olanzapine between January 1996 and May 2001.

Of the patients on olanzapine, seven had newly diagnosed hyperglycemia while two already were identified as diabetics. The sugar disorder developed within a week of taking the drug in two patients and within six months for eight others. (Data are missing for the ninth.)

Sugar control improved in four patients who stopped taking the drug or scaled back their dose. But one patient ultimately died of necrotizing pancreatitis, a condition in which cells in the pancreas die.

One youth taking clozapine also developed pancreatitis more than a month after stopping the drug. That patient survived.

Available information showed that eight of the clozapine patients with high blood sugar never had the problem before. Although the patients on olanzapine also were taking a wide range of other medications, those on clozapine took only one other medication.

Though diabetes linked to obesity is a growing problem among American teens, it is uncommon enough -- one case per 1,000 people under age 25 -- that uncontrolled blood sugar sticks out.

Assuming the number of reported adverse reactions to the two brain drugs accurately reflects their occurrence -- and researchers suspect many more cases weren`t reported -- the researchers estimate the rate of hyperglycemia among young clozapine users is 10 times greater than among the general population. However, the rate for those taking olanzapine doesn`t seem to be elevated, they conclude.

"The million-dollar question is whether the cases in the MedWatch database are the tip of the iceberg or not. We don`t have a good sense for what percent of serious adverse events that occur in practice with marketed drugs are ever reported to the FDA," co-author P. Murali Doraiswamy, a Duke University psychiatrist, says in a statement.

"The connection between pancreatitis and these drugs is not fully known, but given its background rate is so rare, I suspect it`s a drug toxicity," Doraiswamy says in an e-mail interview.

Tawny Bettinger, a brain drug expert at the University of Texas Southwestern Medical Center who has studied the effects of antipsychotics on blood sugar, says the problem is gaining attention among mental health experts. "They don`t know the causes of it, or why it`s happening," says Bettinger, who cites a number of case studies, including one she published, that have appeared in the last several years.

In her own work, Bettinger and her colleagues saw that a diabetic woman taking olanzapine quickly developed runaway blood sugar that previously had been under control with a careful diet. Once the woman started on the drug, even insulin and other sugar-quelling medications couldn`t keep her glucose in check.

Fortunately, Bettinger says psychotic patients who suffer blood sugar disruptions on one medication can take a variety of other drugs.

Meanwhile, The Duke and FDA researchers write, "Atypical antipsychotic agents continue to have a role in treating pediatric psychotic disorders, although they are not currently labeled for pediatric use. Until systematic studies of the various agents are conducted to determine relative and absolute risk, physicians should consider monitoring patients for hyperglycemia."

Koller declined to discuss her study, and officials at the FDA could not be reached for comment on the findings.

Clozapine`s better understood side effect is a potentially grave falloff in white blood cells, a problem called agranulocytosis that the FDA has recognized for some time. Patients starting on clozapine must undergo regular blood tests to watch for the condition.

Last July the drug was linked to dozens of cases of heart complications, including at least 28 deaths since the late 1980s. Novartis, which makes a brand-name version of the pill, has contested those figures. Even so, many mental health experts consider the compound a miracle drug for patients with otherwise untreatable psychosis.

In the United States, warning labels on atypical antipsychotics list the possibility of sugar problems in patients who use them, but they aren`t "highlighted in any special way," Doraiswamy says. "In Japan, they have a much stronger warning that is highlighted and appears at the very first beginning of the label." However, Doraiswamy says, "It`s difficult to further change the label in the United States without having a sense for whether this is a unique problem with one or two drugs or applies to the entire class."

What To Do

A recent report on mental illness from the U.S. Surgeon General says roughly 2.2 million Americans have schizophrenia, split evenly between men and women.

For more on the condition, try NARSAD, the National Alliance for Research on Schizophrenia and Depression or the National Institute of Mental Health.

To learn more about atypical antipsychotics, try About.com.

For more on hyperglycemia, check EndocrineWeb.com or the University of Pennsylvania.



------------------------------------------------------------

[boriz]

servus,

nix neues zu titan ? überlege unter 10 wieder einzusteigen, was sagt ihr ?

greetz,

boriz

[boriz]

tja, hier schein kein interesse mehr an titan zu herrschen. verliert heute auch 10% .... bin nicht neu eingestiegen, halte aber noch altposition..

greetz,

boriz

[Coluche]

Hi,

melde mich hier neu im Board, nachdem ich mich seit ca. 2 Wochen immer mal wieder mit Titan beschäftigt habe und nun über einen Einstieg nachdenke.

Insgesamt sind mir die Beiträge hier im Titan-Board als sachlich und informativ aufgefallen.

Meine persönliche Meinung ist die, daß Titan eine ordentliche Pipeline hat, mit einer Marktkapitalisierung von etwas mehr als 200 Mio. US-$ und ca. 108 Mio US-$ Cash-Reserve, diese Pipeline nur mit etwas mehr als US-$ 120 bewertet und somit meiner Meinung nach deutlich unterbewertet ist.

Habe mich auch mal bei den Sturzas informiert, die zu den renommierten Biotech-Analysten zählen und die Titan mit "strong-buy" bewerten.
Sie berichten, daß die Phase III Studie von Zomaril, die an 600 Patienten getestet wurde folgende Ergebnisse lieferte:
Es wurden 2 Versuchsreihen getätigt mit 12-16 mg/Tag und mit 20-24 mg/Tag. Während die erste Versuchsreihe mit der niedrigeren Dosis kaum signifikant statistische Wirkungen zeigte, zeigte die 2. höherdosierte Versuchsreihe gegenüber der Placebo-Reihe deutliche Verbesserungen bei den Symptomen. Allerdings trat als Nebenwirkung bei der höheren Dosis eine sehr geringe QTc-Wirkung auf ( eine Art Herzrhythmusstörung ), worüber die Fachwelt wohl einig war, das dies nicht signifikant wäre, wohl aber die FDA dazu veranlasst hat, speziell hierzuvon Tita noch zusätzliche Versuchsreihen zu fordern.

Die Sturzas sagen zudem, daß auch ohne Zomaril Titan noch auf Basis der bestehenden Pipeline ein Kauf wäre.

Würde mich feuen, von dem einen oder anderen Boardteilnehmer eine aktuelle Meinung zu Titan ( auch kritisch, wenn sachlich ) zu lesen.

Gruß Coluche

[Erbse1]

Hallo liebe TTP Fans. Hab hier einen Bericht von Novartis zu Leponex (Clozapine) gefunden.
Mittlerweise wird dieses Medikament als Generika hergestellt und die Auswirkungen dürften für Novartis nicht so gravierend sein.
Dieser Bericht deckt sich mit der groß angelegten Untersuchung, die ich vor ein paar Tagen im Cortex Thread veröffentlicht hab. Das Risiko eines Psychotikers einen plötzlichen Herztod zu erleiden ist etwa drei mal so hoch wie bei einem gesunden Menschen.
Die verzögerte Einführung des Medikamentes Geodon (Ziprasidon) ist eben auf die Verlängerung des QT Intervalls zurückzuführen.
Leider zum Nachteil von Titan und Zomaril ist, daß Abilitat von Bristol Meyer halt ein gutes Jahr früher auf dem Markt.
Hier scheint diese Problematik mit dem QT Intervall nicht so gravierend zu sein.
Hier noch der Bericht.
Liebe Grüße
Erbse1
------------------------------------------------------------
Risk of Cardiovascular Toxicity Associated with Schizophrenia Medication Clozapine - Novartis recommends physicians and patients to be alert for symptoms

DORVAL, Quebec, Jan. 18 /CNW/ - After discussions with Health Canada,
Novartis Pharmaceuticals Canada is alerting schizophrenia patients/guardians
and physicians of emerging safety information concerning the cardiac effects
of clozapine, a medication sold in Canada under the tradename Clozaril(R).
Clozaril is an atypical antipsychotic medication, prescribed for patients with
treatment-resistant schizophrenia. Clozaril has been available in Canada since
1991.
Analysis of safety databases suggests that the use of clozapine is
associated with an increased risk of myocarditis, an inflamation of the
muscular walls of the heart. Clozapine is associated with this increased risk
especially during, but not limited to, the first month of therapy.
Specifically, myocarditis has been reported in patients 19 years of age and
older, at dosages within the approved dosage range and during titration of
clozapine. In Canada, there have been 9 reported cases of myocarditis. Of
these, three have been fatal. Given the estimated 15,600 Canadian clozapine-
treated patients as of August 2001, this represents an estimated incidence of
0.06% for all reports of myocarditis (or 1/1667 patients) and 0.02% for
myocarditis fatalities (or 1/5200).
Other cardiovascular events, including pericarditis, pericardial effusion
and cardiomyopathy have also been reported in association with clozapine use,
as have heart failure, myocardial infarction and mitral insufficiency; these
reports include fatalities.

Patients should contact their physician immediately if they develop
persistent tachycardia (rapid heart rate) at rest accompanied by other signs
and symptoms of heart failure (e.g. chest pain, shortness of breath, swelling
of the ankles and feet, or arrhythmias (abnormal heart rhythms). Other
symptoms which may be present in addition to the above include fatigue, flu-
like symptoms, fever that is otherwise unexplained, hypotension (low blood
pressure) and/or raised jugular venous pressure (bulging neck veins when
sitting or standing). Patients are advised to contact their physician before
discontinuing any medication.

The occurrence of such signs and symptoms necessitates an urgent
diagnostic evaluation for myocarditis, cardiomyopathy and/or other
cardiovascular dysfunction by a cardiologist (NOTE: referral to cardiologist
will be needed by treating physician). Patients with a family history of heart
failure should have a cardiac evaluation prior to commencing treatment;
clozapine is contraindicated in patients with severe cardiac disease.
The occurrence of myocarditis and other cardiovascular-related adverse
events in association with Clozaril has been included in the Product Monograph
since the launch of the product in Canada in 1991. The monograph has since
been updated several times to provide further information on emerging safety
data regarding myocarditis, the last update being issued in June 2000.
Novartis is committed to patient safety, and is now alerting
patients/caregivers to be aware of possible symptoms of these potentially
fatal conditions, including cardiomyopathy, and to discuss them with their
physicians.
Novartis has sent a health care professional letter to Canadian
physicians and pharmacists alerting them of these important side effects
associated with Clozaril to enable them to optimally counsel patients. The
Product Monograph for Clozaril will also be expanded to provide additional
background information on the association of cardiovascular toxicity and
Clozaril and valuable information for prescribers on the management of
myocarditis and other cardiovascular-related events. The updated full
prescribing information for Clozaril for healthcare professionals and the
information for the patient/guardian will be posted at http://www.novartis.ca
shortly.

------------------------------------------------------------

[boriz]

servus,

-13,7 % was ist los ? einsteigen oder abwarten, was sagt ihr ?

greetz,
boriz

[boriz]

SOURCE: Titan Pharmaceuticals, Inc.

Titan Pharmaceuticals Announces Initiation of Phase II Clinical Study With CeaVac and TriAb for the Treatment of Colorectal Cancer

Study Supported by the National Cancer Institute

SOUTH SAN FRANCISCO--(BW HealthWire)--Feb. 7, 2002-- Titan Pharmaceuticals Inc. (ASE: TTP) today announced initiation of a Phase II clinical study that will evaluate combination therapy with two of its novel monoclonal antibodies, CeaVac® and TriAb®, for the treatment of Dukes` D colorectal cancer in patients with resected liver metastases.

The Cancer and Leukemia Group B (CALGB), a national clinical research group, is conducting the trial with funding provided by the National Cancer Institute (NCI). The CALGB includes a network of 29 university medical centers, over 185 community hospitals and approximately 3,000 physicians.

The study will assess the safety and preliminary efficacy of CeaVac and TriAb in patients with Dukes` D colorectal cancer that has spread to the liver. Approximately 60 percent of patients with Dukes` D colorectal cancer develop hepatic metastases, or liver tumors. Surgery is often conducted to remove these tumors, however, the majority of patients relapse within two years following surgery. At present, no effective therapy exists for this patient group.

Titan Pharmaceuticals has identified and developed the monoclonal antibodies CeaVac and TriAb as potential treatments for several types of cancer because they both trigger the immune system to recognize and attack targeted cancer cells. CeaVac mimics the carcinoembryonic antigen (CEA), and TriAb mimics the human milk fat globule (HMFG) antigen, both of which are found in high concentrations in colorectal cancer cells, as well as other tumor types.

``In colorectal cancer, tumor cells express both CEA and HMFG in high density,`` stated Mitchell Posner, MD, Chief of Surgical Oncology at the University of Chicago Medical Center and lead investigator of the CALGB study. ``In separate Phase I and Phase II clinical studies, CeaVac and TriAb have each demonstrated the ability to generate excellent immune responses against CEA and HMFG, and we are hopeful that when administered in combination they may provide an enhanced treatment option by simultaneously inducing immune responses against both of these cancer associated antigens.``

``We are very pleased that the CALGB and the NCI have launched this important clinical trial,`` said Dr. Louis R. Bucalo, Chairman, President and CEO of Titan Pharmaceuticals. ``The CALGB study takes advantage of the fact that cancer cells often express more than one tumor associated antigen, thereby presenting multiple targets for the immune system to attack. The difficulty has been in designing a standardized therapy capable of inducing the immune system to mount the attack. In previous clinical studies we have shown that both CeaVac and TriAb have this capability. In addition to CeaVac and TriAb, Titan is also developing a third monoclonal antibody, TriGem®. With three monoclonal antibodies in development, Titan is well positioned to develop an approach to the treatment of various cancer types utilizing these agents in combination to attack tumor cells that express multiple target antigens.``

Additional Ongoing CeaVac and TriAb Clinical Trials

The NCI is also funding a Phase II study of CeaVac and TriAb in patients with non-small cell lung cancer that is being conducted byanother government sponsored clinical cooperative group, the Radiation Therapy Oncology Group (RTOG). In addition to the studies funded by the NCI, Titan is also conducting a randomized, double-blind, placebo controlled Phase III study of CeaVac for the treatment of Dukes` D colorectal cancer, with over 620 patients enrolled at over 50 sites in the United States and Europe.

About Titan Pharmaceuticals

Titan Pharmaceuticals, Inc. (ASE: TTP) is a biopharmaceutical company focused on the development and commercialization of novel treatments for central nervous system (CNS) disorders, cancer and other serious and life-threatening diseases. Titan has assembled a deep pipeline of products utilizing novel technologies that have the potential to significantly improve the treatment of these diseases. Titan also establishes important partnerships with multinational pharmaceutical companies and government institutions for the development of its products. Iloperidone, Titan`s novel drug for the treatment of schizophrenia, is being developed through a corporate partnership agreement with Novartis Pharma AG. Titan has also entered into a corporate partnership with Schering AG to develop and commercialize Spheramine®, a novel treatment for Parkinson`s disease. In addition, several programs in cancer therapy are currently in clinical testing, including studies supported by large oncology cooperative groups that are funded by the National Cancer Institute.

The press release may contain ``forward-looking statements`` within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such statements include, but are not limited to, any statements relating to the Company`s development program and any other statements that are not historical facts. Such statements involve risks and uncertainties, including, but not limited to, those risks and uncertainties relating to difficulties or delays in development, testing, regulatory approval, production and marketing of the Company`s drug candidates, unexpected adverse side effects or inadequate therapeutic efficacy of the Company`s drug candidates that could slow or prevent product development or commercialization, the uncertainty of patent protection for the Company`s intellectual property or trade secrets and the Company`s ability to obtain additional financing if necessary. Such statements are based on management`s current expectations, but actual results may differ materially due to various factors, including those risks and uncertainties mentioned or referred to in this press release.
------------------------------------------------------------------------
Contact:

Company:
Titan Pharmaceuticals
Louis R. Bucalo, M.D.
Tel: [phone]
or
GCI Group
Media:
Alexandra Benarous
Tel: [phone]
or
Investors:
GCI Group
Charlotte Ostor
Tel: [phone]

[Erbse1]

Hier eine Meldung von TTP zu Spheramine. Sollten wirklich heute einige merken, dass TTP nicht nur Zomaril in der Entwicklung hat, die ja wie bekannt etwa um ein gutes Jahr zurückgefallen sind.
Liebe Grüße
------------------------------------------------------------
Titan Pharmaceuticals Announces Milestone Payment From Schering AG in Development Program for Spheramine
SOUTH SAN FRANCISCO, Calif.--(BW HealthWire)--Feb. 21, 2002--Titan Pharmaceuticals, Inc. (ASE: TTP) today announced that it has received a $2 million milestone payment from Schering AG (FSE: SCH, NYSE: SHR), Titan`s corporate partner for worldwide development, manufacture and commercialization of Spheramine(TM), Titan`s novel cell therapy for the treatment of Parkinson`s disease.

The milestone payment follows the recent successful completion of Titan`s Phase I/II clinical study of Spheramine, and the decision to initiate larger, randomized clinical testing of Spheramine for the treatment of late-stage Parkinson`s disease. Data from the recently completed 12-month study will be presented at medical conferences later this year.

Spheramine is a novel cell therapy consisting of retinal pigment epithelial (RPE) cells adhered to microscopic carriers. RPE cells are normal, mature human cells that are implanted into the central nervous system to produce dopamine, a neurotransmitter that is deficient in the brains of Parkinson`s disease patients. RPE cells are fully developed and differentiated cells, thereby potentially eliminating concerns associated with other approaches, such as use of embryonic neuronal cells or stem cells that can migrate and change after implantation. The elimination of the variables associated with post-implantation migration and differentiation is an important potential advantage for Spheramine.

``Successful completion of the Phase I/II clinical study is an important milestone in the Spheramine product development program,`` stated Dr. Louis R. Bucalo, Chairman, President and CEO of Titan.

``We are pleased with the continued progress of this development program,`` stated Dr. Joachim-Friedrich Kapp, Head of the Strategic Business Unit Specialized Therapeutics of Schering AG. ``Preliminary results from the pilot clinical study are very encouraging, and we now look forward to further clinical testing of Spheramine.``

Preliminary data from the Phase I/II clinical study presented last year at the American Academy of Neurology meeting and the International Congress on Parkinson`s Disease demonstrated improvement in motor function and quality of life for late-stage Parkinson`s disease patients treated with Spheramine.

Spheramine is based on Titan`s proprietary cell-coated microcarrier (CCM(TM)) technology. CCM technology adheres cells to inert, microscopic carriers that can then be implanted into the central nervous system. This confers greatly improved survival to the cells and avoids the need for immunosuppression (suppression of the immune system in order to prevent rejection). Spheramine is the first Titan product using this technology.

------------------------------------------------------------

[Erbse1]

Hallo liebe TTP Fans, hallo Puhvogel. Hab hier einen Artikel zu Ziprasidon = Zeldox = Geodon gefunden.
Geodon hat nach einem Jahr der Markteinführung einen Marktanteil in den USA von über 10% erreicht.
Solch einen Marktanteil in so kurzer Zeit erreichte meines Wissens in etwa nur Zyprexa. Zyprexa hat zur Zeit in etwa einen Marktanteil von 28 %.
Meine Spekulation, daß der Trend verstärkt zu den neuen Medikamenten geht, wird wohl aufgehen.
Demnächst steht ja noch Abilitat von Bristol Meyers und Zomaril von TTP an.
Folgend noch der Artikel zur Markteinführung in einige europäische Länder.
Liebe Grüße
Erbse1
------------------------------------------------------------
To Launch Zeldox In 9 European Union Countries Beginning Next Month



New Antipsychotic Medicine Will Provide Important

New Treatment Option for Patients with Schizophrenia

DAVOS, Switzerland, Feb. 25 /PRNewswire-FirstCall/ -- Pfizer Inc said today that it plans to introduce its atypical antipsychotic Zeldox(R) and Zeldox(R) IM (ziprasidone HCl and ziprasidone mesylate) in both capsule and intramuscular formulations in the European Union. The new medicine, which will provide an important new treatment option for patients with schizophrenia, was first launched in Sweden in 2000 and will become available in nine other EU member states beginning with Denmark in March.

Discovered and developed by Pfizer, Zeldox is a serotonin and dopamine antagonist. Zeldox capsules have been proven effective in treating symptoms characterized as both positive (e.g. visual and auditory hallucinations) and negative (lack of motivation and social withdrawal) as well as in the treatment of overall psychopathology. Intramuscular Zeldox, which will be the first injectable atypical antipsychotic available in Europe, is used to control agitated behavior in patients with schizophrenia.

"Zeldox will provide important new treatment options for both the acute and chronic phases of schizophrenia," said Dr. Joseph Feczko, Pfizer`s senior vice president of medical and regulatory operations. The launch announcement was made at the Winter Workshop on Schizophrenia, a biennial meeting of schizophrenia researchers here in Davos.

Zeldox has been approved for use in 31 countries. The medicine was approved by the U.S. Food and Drug Administration on Feb. 5, 2001, and is known as Geodon(TM) in the United States. Since then more than 156,000 patients in the United States alone have been prescribed Geodon capsules. Zeldox also is available in Brazil, Argentina, Mexico and the Czech Republic.

Schizophrenia is a life-long illness that affects approximately one percent of the world`s population and takes a huge financial toll on health care systems. Schizophrenia typically strikes men and women in their late adolescence or early 20s and is chronic, often with multiple relapses and impaired daily functioning.

"Because schizophrenia is difficult to treat and manage, patients are in need of new, safe and more effective treatment options," said Dr. W. Wolfgang Fleischhacker, who heads the Department of Biological Psychiatry at Innsbruck University Clinics in Austria. It is estimated that up to 30 percent of patients with schizophrenia are not optimally controlled on their current medications.

Acute agitation in patients with psychosis is one of the most common psychiatric emergencies and is characterized by uncooperative or even violent behavior. Injectable medicines are important in this setting because of their rapid onset of action.

However, currently available acute therapies frequently result in excessive sedation and debilitating movement disorders that patients find very distressing. Injectable Zeldox has shown a favorable side effect profile when compared to conventional therapies with significantly fewer movement disorder

"With intramuscular Zeldox and Zeldox capsules, health care providers will now have in a single atypical medicine a continuum of care for both the agitated patient as well as for the long-term management of schizophrenia," Dr. Feczko said. "In addition to efficacy, Zeldox capsules have a unique tolerability profile with respect to weight gain, lipids and insulin levels, which are increasingly recognized as important cardiovascular risk factors."

Following a March 8 launch in Denmark, Zeldox will be introduced in Germany, Norway, Austria, Luxembourg, Portugal, and Iceland. The medicine will be launched in Ireland and Greece as Geodon. Pfizer said it is committed to making Zeldox available to patients elsewhere in Europe as soon as possible.

In short-term studies, the most common side effect associated with Zeldox capsules was somnolence, which was generally characterized as mild to moderate in severity and rarely led to discontinuation of treatment. The most common side effects associated with intramuscular Zeldox were injection-site pain, nausea, somnolence and dizziness.

Zeldox capsules or injections must not be used by patients with known QT interval prolongation, congenital long QT syndrome, a recent myocardial infarction, uncompensated heart failure or by patients taking certain medicines that prolong the QT interval.

Pfizer Inc discovers, develops, manufactures and markets leading prescription medicines, for humans and animals, and many of the world`s best known consumer brands.

------------------------------------------------------------

[Braini]

6.5% + bei 2% minus an der nasdaq... was war los , weiss jemand was ??

[puhvogel]

Na, so wundern würde ich mich nun wirklich nicht. Der Kurs ist ja schon bald mit den Bargeldbeständen zu rechtfertigen.

[Braini]

langsam gehts wieder aufwärts .. wird auch zeit

[eueropa]

Schnallt euch an die Post geht ab !

[eueropa]

Hallo Ihr TITAN Fans!

Gibts nichts neues ???

[eueropa]

Keiner schreibt mehr was zu TITAN ! Habt Ihr sie schon aufgegeben? Ich habe heute 250 Stück zugekauft auf folgende news hin:
Press release April 10, 2002

Titan Reports Positive Results From Studies of Two Cancer Treatments in Development

Data from Separate Studies of Pivanex(TM) and RB94 Presented This Week at American Association of Cancer Research

SOUTH SAN FRANCISCO, Calif.--(BW HealthWire)--April 10, 2002-- Titan Pharmaceuticals, Inc. (ASE:TTP) reported today that new studies have further demonstrated that Titan`s novel, small molecule drug Pivanex(TM) has significant anti-tumor activity in preclinical studies of lung cancer and bladder cancer, and may be combined with current chemotherapeutic agents to increase anti- cancer activity.

Titan also reported in separate studies that RB94 gene therapy demonstrated potent anti-tumor effects and growth inhibition in a preclinical model of head and neck cancer, and can be combined with cisplatin, a current therapy for this disease, to further enhance tumor destruction.

The studies, presented at the 93rd annual meeting of the American Association of Cancer Research (AACR), were also significant in demonstrating novel biologic mechanisms of action for each of these proprietary products in development. The findings collectively provide strong support for the potential of these agents to contribute to improved cancer therapy.

Pivanex Studied in Combination with Chemotherapy

Pivanex, which attacks cancer cells through changing the expression of cancer-related genes, is currently in Phase II clinical testing in lung cancer. In the newly-reported studies, human bladder and non-small cell lung cancer cells were evaluated to test the anti- tumor activity of Pivanex in combination with different chemotherapy agents (gemcitabine, cisplatin, paclitaxel and docetaxel) for the effect on tumor cell growth and oncogene expression. These cell lines were selected because they differ in sensitivity to chemotherapy agents and in oncogene expression.

Results of the study showed that combination therapy increased anti-tumor activity:

In non-small cell lung cancer cells, Pivanex was synergistic with docetaxel, and additive with cisplatin or gemcitabine in inhibiting tumor cell growth.
In non-small cell lung cancer cells resistant to chemotherapy, Pivanex overcame resistance to paclitaxel and was synergistic with cisplatin.
In bladder cancer cells, Pivanex was additive with cisplatin and synergistic with gemcitabine.

Data also showed that Pivanex decreased oncogene expression in the cancer cell lines examined.

``These data build upon the extensive body of scientific evidence that we have in both preclinical and clinical settings supporting the anti-tumor activity of Pivanex,`` said Tony Reid, M.D., Ph.D., a researcher at Stanford University and the Palo Alto Veteran`s Administration Hospital. ``Combining Pivanex with chemotherapy may be an important approach that will enable us to offer our patients less toxic treatments with potentially better results.``

Traditional chemotherapeutic drugs often kill both cancer cells and normal cells, thereby causing systemic side effects such as anemia, nausea, vomiting and risk of infection. Unlike these traditional cancer therapies, Pivanex is a non-myeloablative and non-myelosuppressive drug, and induces changes in gene expression in cancer cells, causing them to undergo apoptosis (programmed cell death).

RB94 in Combination with Chemotherapy

RB94 is a gene therapy product being developed by Titan as a potential treatment for several cancers, including head and neck, lung and pancreatic cancer. Adenovirus-mediated RB94 (Ad-RB94) gene delivery was studied in combination with the chemotherapeutic agent cisplatin in a head and neck squamous cell carcinoma (HNSCC) mouse model to evaluate the benefit and mechanism of this combination therapy. Tumor size was measured before and after treatment with Ad-RB94, cisplatin and control adenovirus alone or in combination, and the mechanism was evaluated through cell cycle analysis and examination for the induction of apoptosis.

Results from the study showed that treatment with Ad-RB94 and cisplatin together produced a statistically significant increase in anti-tumor activity as compared to cisplatin treatment alone. Additionally, the combination of Ad-RB94 with low dose cisplatin was found to be as potent in tumor destruction as toxic doses of cisplatin alone, without the associated toxicity. The study also demonstrated that Ad-RB94 has significant anti-tumor activity as a single agent.

This study also further supports the unique mechanisms of RB94 function that have been shown in previous studies in cancer models. Data showed that the combination of Ad-RB94 gene delivery and cisplatin significantly increased tumor cell arrest at critical chemotherapy-sensitive points in the cell cycle (G2/M and S phases), and increased tumor cell apoptosis, when compared to other treatment groups. The results suggest that these mechanisms could contribute to the significant increase in anti-tumor activity.

``These findings indicate that Ad-RB94 can be combined with chemotherapy to produce a more potent cancer treatment without increased toxicity,`` said Bert W. O`Malley, Jr., M.D., chairman of Otolaryngology, Head and Neck Surgery, at the University of Maryland School of Medicine. ``We are excited about the prospect of bringing this treatment modality to the clinic because there is a real need for more effective therapies, and RB94 gene therapy is an important new strategy.``

RB94 is a modified version of the retinoblastoma (RB) gene, a tumor suppressor gene that is directly involved in regulating the cell cycle and causing apoptosis. The RB gene plays an important role in cell replication and in preventing cancerous cell transformation and proliferation. Loss of RB gene activity is associated with a majority of solid tumor cancers.

Commenting on the results of the two studies presented at AACR, Titan Chairman, President and CEO Dr. Louis R. Bucalo said, ``We are very encouraged by the positive results of these studies which support the advancement of both Pivanex and RB94 into additional clinical settings.``

Titan is currently developing Pivanex and RB94 for several types of cancer. According to the World Health Organization`s International Agency for Research on Cancer, head and neck cancer affects more than 600,000 people, pancreatic cancer more than 200,000 people, and lung cancer more than 1.2 million people worldwide, respectively.

[erkilein]

Thursday April 18, 8:13 am Eastern Time
Press Release
SOURCE: Titan Pharmaceuticals, Inc.
Titan Announces Positive Long-term Results of Phase I/II Study of Spheramine in Parkinson`s Disease
SOUTH SAN FRANCISCO, Calif.--(BW HealthWire)--April 18, 2002-- Titan Pharmaceuticals, Inc. (ASE:TTP)

Data Presented at American Academy of Neurology Demonstrate

Significant Improvement in Motor Function

in Late-Stage Parkinson`s Patients

Titan Pharmaceuticals, Inc. (ASE:TTP) today announced that treatment with Spheramine® produced a nearly 50 percent improvement in motor function in patients with advanced Parkinson`s disease in a recently completed, 12 month Phase I/II study. Spheramine is a novel cell therapy product for the treatment of Parkinson`s disease being developed by Titan in collaboration with Schering AG (FSE:SCH, NYSE: SHR), Titan`s corporate partner for the development of Spheramine.

The new data, presented today at the 54th annual meeting of the American Academy of Neurology, also demonstrated significant improvement in quality of life for all patients treated, with no significant adverse events. Based upon the positive results of this study, Titan and Schering are preparing to initiate a randomized clinical study of Spheramine.

``The long-term results from this pilot clinical study with Spheramine are very favorable and confirm the preliminary findings of the study,`` said Ray L. Watts, M.D., professor and vice chairman of the Department of Neurology at Emory University School of Medicine and principal investigator of the study. ``These data indicate that this new approach may hold significant promise for improved treatment of Parkinson`s patients.``

Positive Efficacy and Safety Results Seen

The open label Phase I/II study in six patients with advanced PD was designed to evaluate the safety of Spheramine and its efficacy in improving motor function. Patients were evaluated pre- and post-treatment, both `on` and `off` their normal medication, using the Unified Parkinson`s Disease Rating Scale (UPDRS), a standard measure of Parkinson`s disease severity. The primary efficacy endpoint was the `off` state motor score of the UPDRS at 12 months, which was evaluated pre-treatment and every three months thereafter.

All patients demonstrated significant improvement in motor function, and other outcome measures, with no safety concerns. At 12 months post treatment:

Patients experienced an average 48 percent improvement in motor UPDRS score, off all other medication.
Patients experienced an average 43 percent improvement in total UPDRS score.
Improvements were noted in quality of life and activities of daily living.
Half the patients demonstrated a reduction in pre-existing dyskinesias (involuntary movements) while the remainder had no change from baseline.
No `off` state dyskinesias were observed (patients off PD medication overnight).
All six patients completed the one-year study, with no safety concerns.
Patients will continue to be monitored beyond the one-year study.

``We are very pleased with the success of this pilot study and look forward to advancing the Spheramine development program into randomized, clinical testing in the near future,`` said Dr. Joachim-Friedrich Kapp, head of the Strategic Business Unit Specialized Therapeutics of Schering AG.

Spheramine and Parkinson`s Disease

In Parkinson`s disease, a neurotransmitter called dopamine is deficient in certain brain regions causing progressive motor symptoms such as tremors, rigidity, and slowed, difficult movements of the arms and legs. Spheramine consists of normal human cells that provide dopamine (RPE cells) attached to microcarriers, and is designed to deliver dopamine to the regions of the brain affected by Parkinson`s disease. In this study, Spheramine was delivered unilaterally to the brain. Subsequent studies of Spheramine will utilize bilateral treatment, which may further enhance the therapeutic profile.

``The positive clinical study results demonstrate the potential of Spheramine to contribute significantly to the treatment of Parkinson`s patients and we look forward to further clinical testing,`` said Louis R. Bucalo, M.D., chairman, president and CEO of Titan. ``In addition, these data further support the broad potential value of Titan`s CCM technology on which Spheramine is based.``

Clinical Results Driven by Broadly Enabling Technology

Spheramine utilizes Titan`s novel cell-coated microcarrier (CCM(TM)) technology, which allows normal human cells to survive after surgical injection into the brain. Cell therapy for the treatment of central nervous system (CNS) disorders is normally limited by death of most of the transplanted cells after a few weeks. By maintaining their viability and function, Titan`s innovative technology allows the use of normal mature cells, rather than embryonic or stem cells, and eliminates the need for drugs to suppress rejection of the cells. This breakthrough technology potentially allows any cell type to be used in neural transplantation, moving the science of CNS cell therapy beyond stem cells to numerous other cell types.

Numerous scientific studies have demonstrated the efficacy of Titan`s CCM technology, which allows normal cells to survive implantation to the brain and provide therapeutic activity. Separately reported, controlled studies in animal models of Parkinson`s disease(1-3) and glioma(4), have confirmed the therapeutic potential of this platform technology. Additional controlled, preclinical efficacy studies will be presented at the International Society for Cellular Therapy in May.

------------------------------------------------------------

Wednesday April 17, 4:46 pm Eastern Time
Reuters Business
Eye cell transplants aid Parkinson`s patients

By Maggie Fox, Health and Science Correspondent

WASHINGTON, April 17 (Reuters) - Eye cells transplanted into the brains of Parkinson`s patients have markedly improved their symptoms and may provide an alternative to steadily increasing doses of medication, doctors said on Wednesday.


The eye cells produce dopamine, the important chemical lacking in the brains of people with Parkinson`s, whose disease begins with trembling or stiffness and progresses to a rigidity that leaves them virtually paralyzed.

Dr. Ray Watts, a professor of neurology at Emory University School of Medicine in Atlanta, said six patients who got the eye cell transplants showed a regression of their symptoms.

``We`ve been following these six participants for over a year, and we`ve found they`ve improved, on average, nearly 50 percent in motor function,`` Watts, who presented his findings to a meeting in Denver of the American Academy of Neurology, said in a statement.

The cells used are found in the retina, the lining of the back of the eye.

``They make dopamine and you can grow them well in culture,`` Watts said in a telephone interview. ``You can produce hundreds of millions of cells from a single donor.``

Watts said no one knows why the cells produce dopamine, a neurotransmitter or message-carrying chemical that, in the brain, is associated with movement.

It is the loss of dopamine-producing neurons in the brain that causes Parkinson`s.

MANY DIFFERENT CELL TRANSPLANTS TRIED

Many researchers are trying different kinds of transplants to treat Parkinson`s, which affects more than a million people in the United States alone. These include cells from pig fetuses, from human fetuses and stem cells, the body`s master cells that can sometimes be induced to form brain tissue.

Watts`s team used retinal cells taken from the bodies of people who donated their eyes after death. There is little risk of an immune system rejection because the brain does not have the same level of immune activity as the rest of the body.

The cells were prepared with a gelatin product called Spheramine, developed by South San Francisco-based Titan Pharmaceuticals, Inc. (AMEX:TTP - news).

``These cells are making L-dopa and or dopamine and serve, in the brain, as a more continual production site than just taking medications by mouth every two hours,`` Watts said.

L-dopa is one of the standard treatments for Parkinson`s and Watts said the improvement he saw in the patients was comparable to when they take the drug.

Standard tests used to measure a patient`s tremors, ability to move and other symptoms showed they got better after the implants, Watts said.

``At 12 months they averaged a 48 percent improvement, which is substantial,`` he said. One patient had a 60 percent improvement. One patient had had the implants for nearly two years and maintains the benefits.

``Not everybody has the same symptoms, but if they had slowness and stiffness and trouble walking generally, those were the symptoms that got better,`` Watts said.

The problem with drugs given to Parkinson`s patients is that the effects wear off more and more quickly as the disease progresses. Patients have to take bigger doses.

``Then they start to get complications,`` Watts said. Sometimes these complications are as bad as the initial Parkinson`s symptoms.

``We need more sustained delivery mechanisms,`` Watts said. ``These cells are one approach to that for patients with advanced Parkinson`s who are not optimally controlled with their medications.``

Ich bin auch mal wieder im Boot zu 6,00 $.

[Erbse1]

Hallo liebe TTP Fans. Hier eine Meldung zu den Konkurenten von Zomaril. Es scheint, daß mit Geodon eine prächtige Alternative zu Haldol in der Akutbehandlung exestiert. Für die Patienten ist das natürlich eine Super Nachricht. Geodon wird in Deutschland unter dem Namen Zeldox vertrieben. Nach dem Kursverlauf der letzten Monate werden Zomaril ja nur noch wenig Chancen eingeräumt.
Liebe Grüße
Erbse1
------------------------------------------------------------
New Study Shows Pfizer`s (PFE) Geodon IM Is More Effective Than Haldol IM In Emergency Treatment Of Patients With Acute Exacerbation Of Schizophrenia



Geodon Associated With Significantly Lower Incidence of

Movement Disorders than Treatment Standard Haldol

PHILADELPHIA, May 22 /PRNewswire-FirstCall/ -- Pfizer Inc`s intramuscular (IM) antipsychotic Geodon (ziprasidone) has been shown to be more effective than the treatment standard Haldol (haloperidol) IM in relieving acute psychotic symptoms among schizophrenia patients in emergency settings, according to data presented today at the 155th annual meeting of the American Psychiatric Association.

An analysis of this open-label study involving more than 500 patients showed that patients who were treated with intramuscular Geodon had comparable improvement in their agitation and greater improvement in their psychotic symptoms than patients who received intramuscular Haldol.

During this acute exacerbation phase of schizophrenia, patients received their medication by intramuscular injection during the first one to three days of treatment. After up to three days of intramuscular dosing, all patients were transitioned to oral therapy for continued management of their schizophrenia symptoms for six weeks. Psychotic symptoms such as hallucinations and agitation were measured by standard assessment scales.

In this study, Geodon IM was more effective than Haldol IM in improving psychotic symptoms and as effective in reducing agitation. The improvement seen in the ziprasidone patients was either sustained or increased when they transitioned to oral therapy. In two other studies comparing Geodon to Haldol, comparable efficacy was demonstrated for the IM and oral formulations.

In addition, patients treated with Geodon during intramuscular administration and oral phases of the study showed a significantly lower incidence of movement disorders than those who received Haldol. Movement disorders are particularly disturbing to patients and may contribute to non-compliance with medication among the schizophrenia patient population. Haldol is one of the most commonly used medications to manage acute agitation and psychosis in the emergency room setting.

"One of the most important periods of treatment for schizophrenia patients is the emergency setting," said David G. Daniel, MD, lead investigator and Clinical Professor of Psychiatry at George Washington University. "Patients come into the emergency room in distress, and therefore rapid control of their psychotic agitation is imperative."

Acute agitation is one of the most common psychiatric emergencies and is characterized by uncooperative and even aggressive behavior. Because patients require immediate intervention, intramuscular antipsychotic medicines are critical because they are rapidly effective.

"Geodon IM represents an important medical advance in helping to rapidly bring agitated patients under control with a low liability for the movement side effects that can be so frightening and debilitating to the patient," Dr. Daniel said.

The most common side effect associated with Geodon IM in this study was insomnia. With Haldol IM, the most common side effects were insomnia and a variety of movement disorders including akathesia, dystonia, extrapyramidal symptoms and hypertonia.Discovered and developed by Pfizer, Geodon is a serotonin and dopamine antagonist. Geodon IM is under regulatory review in the United States. Geodon is the first atypical antipsychotic approved in intramuscular formulation in more than 15 countries, including Germany, Sweden, Spain and Brazil.

Oral Geodon received U.S. Food and Drug Administration approval for use in the treatment of schizophrenia in February 2001. It also is approved in more than 30 countries worldwide.

Oral Geodon is associated with a prolongation of the QTc interval of the electrocardiogram, an effect seen with certain other marketed medicines, including some antipsychotics. This effect was well characterized in the extensive oral Geodon clinical trials database and is reflected in the FDA`s product labeling, which suggests that physicians use their best judgement, based on the overall status of the patient, as to whether Geodon or another antipsychotic agent be used first.

------------------------------------------------------------

[Erbse1]

Auch von Abilitat (Aripiprazole) gute Nachrichten. Abilitat dürfte wohl bald zugelassen werden und damit wäre Zomaril wohl nur das dritte Medikament seiner Klasse auf dem Markt.
Dennoch notiert Titan schon fast am Cashbestand. Für chancenlos halte ich Zomaril allerdings auch nicht, da nicht jeder Patient jedes Medikament verträgt. Dennoch dürfte sich Zomaril wohl hinter Geodon und Abilitat einreihen.
Liebe Grüße
Erbse1
------------------------------------------------------------
Bristol schizophrenia drug matches older treatment

(adds details, quotes, share price)

By Ransdell Pierson

NEW YORK, May 22 (Reuters) - A new schizophrenia drug being developed by Bristol-Myers Squibb Co. (NYSE:BMY - News) showed effectiveness similar to a standard anti-psychotic in clinical trials, but with fewer of the side effects, such as weight gain and shaking, seen with some medicines, researchers said on Wednesday.
ADVERTISEMENT



The new studies were described at the annual meeting of the American Psychiatric Association being held in Philadelphia.

They bolster earlier short-term studies in which Bristol`s experimental drug, aripiprazole, controlled schizophrenia in seriously ill hospitalized patients with only mild side effects.

Aripiprazole is the first in a new class of drugs that works mainly by stabilizing dopamine, but also regulates another chemical called serotonin.

A new, year-long trial involved almost 1,300 patients with acute relapses of schizophrenia symptoms, two-thirds of whom were treated daily with the Bristol drug. Remaining patients took haloperidol, a generic medicine sold by Johnson & Johnson (NYSE:JNJ - News) as Haldol that causes tremors and other neurological side effects.

Patients taking both drugs showed similar relief from "positive" symptoms of the disease, such as hallucinations and paranoia, researchers said.

But those taking the Bristol drug were better able to shake off "negative" symptoms of the brain disease such as lack of enthusiasm and withdrawal from others, said Dr. Daniel Casey, a psychiatrist at the Veterans Affairs Medical Center in Portland, Oregon, who was a lead researcher for the studies.

Neither group of patients experienced significant gains in weight, a common problem among patients taking Eli Lilly and Co.`s (NYSE:LLY - News) top-selling Zyprexa and, to a lesser extent, Johnson & Johnson`s newer treatment, Risperdal.

Likewise, neither aripiprazole nor haloperidol caused prolongation in the QTc interval, an irregular effect on electrical conduction in the heart that has been associated with Pfizer Inc.`s (NYSE:PFE - News) schizophrenia drug, Geodon.

Those taking aripiprazole had significantly fewer incidents of shaking and uncontrolled movements than those taking haloperidol, Casey said, a possible reason why significantly fewer patients treated with the Bristol drug discontinued therapy during the trial.

"Aripiprazole could offer major advantages over current drugs because it doesn`t cause weight gains, neurological side effects or have an effect on the QTc interval," Casey said.

"Aripiprazole is able to recognize what the dopamine environment is and regulate it," said Mary Kujawa, a senior Bristol-Myers research executive.

Excessive amounts of dopamine in parts of the brain are believed to cause positive symptoms of schizophrenia, a disease that afflicts an estimated 1 percent of the population. Likewise, low amounts of dopamine in other brain regions have been linked to negative symptoms.

It is designed to block dopamine where it is excessive, and stimulate it where supplies are too low.

By contrast, Kujawa said current treatments only block dopamine and serotonin, instead of regulating them up and down as needed.

Shares of Bristol-Myers were up $1.03, or 3.4 percent, to $31.12 in afternoon trade on the New York Stock Exchange.

Bristol filed a U.S. marketing application for aripiprazole last November. It is counting on the drug to become a big enough seller to help get the firm`s earnings back on track following the recent loss of patent protection on its key medicines for cancer, anxiety and diabetes.

In a related eight-week trial involving 311 stable schizophrenia patients, Casey said those switched to Bristol`s drug from Zyprexa and Risperdal showed an improvement in symptoms and reduction in certain side effects, such as weight gain.

------------------------------------------------------------

[Mr.Arrogance]

man sollte sich die frage stellen:
was ist ttp wert ohne iloperidone?

der hoffnungsträger nr.1 ist zwar noch nicht ganz gescheitert, scheint jedoch im besten fall die dritte geige zu spielen. diese problematik hat jedoch schon mitte letzten jahres zu einem drastischen kurseinbruch geführt.

gut möglich, dass iloperidone gänzlich scheitert. was bleibt dann übrig?
- spheramine, dann wohl hoffnungsträger nr.1
- ceavac
- weitere produktpipeline dürfte in nächster zeit für die bewertung vernachlässigbar sein

beruhigend der ordentliche cashbestand von ca.$90mio, bei quartalsverlusten zuletzt etwa $5mio.

welchen wert kann man spheramine + ceavac zubilligen?

mr.A

[puhvogel]

Na erst einmal muss Aripiprazole durch die FDA -Mühle kommen, heutzutage keine Selbstverständlichkeit, schon gar nicht, wenn Präparate auf dem Markt existieren.

[Erbse1]

Hallo Puhvogel.
Natürlich hast du Recht mit der Zulassung. Dennoch sehe ich sehr große Chancen bei Aripiprazole und Zomaril, da sie in Ihrer wirkweise vollkommen neu sind. Durch ihre Affinität zu den Serotoninrezeptoren kann bei vielen Patienten auf eine zusätzliche Gabe von Antidepressiva verzichtet werden. Wir sollten nicht vergessen, daß die alten Medikamente doch mit enormen Nebenwirkungen in Verbindung gebracht werden. Mich würde es sehr wundern, wenn Aripiprazole nicht zugelassen würde. Selbst das neue Geodon birgt ein enormes Risiko durch die Verlängerung des QT Intervalls. Ich hab schon mal an anderer Stelle darauf hingewiesen, daß Das Risiko eines Psychotikers einen plötzlichen Herztod zu erleiden, etwa dreimal so hoch ist wie in der normalen Bevölkerung. Bei Aripiprazole scheint dieses Problem ja nicht vorzuliegen.
Bei TTP werden ja bald die Ergebnisse zu den kardiologischen Untersuchungen vorzuliegen.
@ Mr. Arrogance Für mich ist die restliche Pipeline von Titan nur sehr schwer einzuschätzen, da sich bisher noch keiner mit den Erfolgsaussichten der Krebspräperate und von Spheramine beschäftigt hat. Allerdings bekommt man die gesamte Pipeline gemessen an den Cashreserven jetzt fast umsonst. Mein Augenmerk richtet sich auch nicht mehr zu sehr auf Zomaril. Ich beobachte da schon die Neuentwicklungen der Konkurrenz auf dem Schizophreniemarkt z. B. Cortex Pharmaceuticals
Liebe Grüße
Erbse1

[Erbse1]

Hallo liebe TTP Fans. Hab hier noch einen Artikel zu Abilitat gefunden. Es scheint verhext zu sein. Irgendeinen dicken Nachteil gibt es bei jedem Psychosemedikament.
Was hier so harmlos als Sitzunruhe betittelt wird, ist oftmals der Hauptgrund, warum die Patienten die Medikamente absetzen. Diese Sitzunruhe ist für die Patienten kaum zu ertragen und der Ausdruck beschreibt diese sehr unangenehme Nebenwirkung nur unzureichend.
Wir müßen tatsächlich die Endergebnisse von Zomaril abwarten. Es könnte sein, daß Zomaril sich doch noch zum Medikament der ersten Wahl entwickeln könnte.
Folgend noch der Artikel über Abilitat.
Liebe Grüße
Erbse1
------------------------------------------------------------
ARIPIPRAZOLE emerging as next great hope for Schizophrenia
Aripiprazole (Abilitat) is being touted as the first member of the new generation of atypical antipsychotic drugs. This once-daily novel antipsychotic has undergone a number of studies, revealing that aripiprazole is significantly better at controlling both the positive and negative symptoms of schizophrenia than placebo and has equaled haloperidol and risperidone in its ability to control these symptoms. Currently, aripiprazole is awaiting FDA approval. On October 31, 2001, Bristol-Myers Squibb and Otsuka Pharmaceutical Co. filed a New Drug Application (NDA) with the FDA and the two companies anticipate the launch of aripiprazole late in the third quarter of 2002.

Stephen M. Stahl, M.D., Ph.D., Professor of Psychiatry at the University of California at San Diego, places aripiprazole in the class of antipsychotics called dopamine system stabilizers (DSSs). Stahl dubs these new therapeutic agents “Goldilocks” because of their ability to strike a balance between too much and too little dopamine. With “just right” result, negative and cognitive symptoms are reduced and motor side effects or prolactin elevation is absent. Previous atypical drugs block dopamine D2 receptors resulting in motor side effects such as pseudo-parkinsonism, and ultimately tardive dyskinesia.

Robert McQuade, Ph.D., director of Global Medical Marketing for Bristol-Myers Squibb, cites the evolution of antipsychotic medications and how their mechanisms of action have changed over time. “The big disadvantage was the side effects,” he says. “The atypicals were designed to address symptoms such as EPS, but brought about different side effects.” Each drug within the atypical category elicited its own particular adverse event, according to McQuade. Literature suggests, he says, that olanzapine causes weight gain, ziprasidone increases the QTc interval and risperidone increases plasma prolactin. “These drugs solved some problems, but created others.” “From a psychopharmacologic viewpoint, aripiprazole is bringing new science to the field,” he says. Unlike the older atypical antipsychotics that reduce positive symptoms of psychosis, such as delusions and hallucinations, by blocking D2 receptors, aripiprazole stabilizes or modulates them. McQuade underscores the multi-faceted benefits of aripiprazole based on the results of several controlled trials, some of which lasted up to 52 weeks in duration, involving more than 3,400 patients with schizophrenia. Aripiprazole was statistically superior to placebo on positive and negative symptoms and superior to haloperidol for negative symptoms, according to McQuade. “Aripiprazole delivers a package of tolerability that enhances the benefit to the patient and thus enhances compliance,” he concludes.

Potential problem with akathisia

According to Larry Ereshefsky, Pharm.D., professor of pharmacy, pharmacology and psychiatry at the University of Texas Health Science Center at San Antonio, the novel partial dopamine agonist mechanism of action augments the 5-Htla and 5-HT2 effects of aripiprazole. “These effects should lead to greater dopaminergic throughput and cortical activity which is good for thinking,” says Ereshefsky. “But it also might possibly explain the increased rates of akathisia at the middle doses (15 mg/d) in some studies. There is clearly a greater effect on the Barnes akathisia scale than from risperidone, and about half the effect of haloperidol.” Ereshefsy adds, “Akathisia is a potential side effect which bares further evaluation in long-term studies to see whether it abates.”

(Akathisia is having a feeling of inner restlessness and the urge to move, rocking while standing or sitting, lifting of the feet as if marching on the spot, and crossing and uncrossing of the legs while sitting.)

Article from Psychopharmacology Update published February 2002.

------------------------------------------------------------

[erkilein]

der chart nimmt bedenkliche formen an, keine gegenwehr, sieht nach einem ziel von 2-3 $ aus, unterstützung von ´98-99

[BonMala]

03.06.2002
Titan Pharma 200%-Kandidat
Global Biotech Investing

Die Experten vom Börsenbrief "Global Biotech Investing" sehen in der Aktie von Titan Pharma (WKN 914404) einen 200%-Kandidaten.

Das Unternehmen konzentriere sich auf die Forschung von Wirkstoffen zur Behandlung von Krebs sowie Erkrankungen des Zentralen Nervensystems. Neben dem am weitesten Fortgeschrittenen Medikament in der Forschungspipeline Iloperiodone habe Titan derzeit noch sieben weitere Produkte in den klinischen Forschungen.

Das Unternehmen habe fast 100 Mio. US-Dollar Cash auf der Bank, was ca. 3,5 US-Dollar je Aktie entspreche. Bei einem aktuellen Kurs von 4,5 US-Dollar werde die gesamte Forschungspipeline des Konzerns gerade einmal mit einem Dollar je Aktie bewertet. Erst letzte Woche habe Deutsche Bank Securities erneut eine "strong buy"-Empfehlung für den Titel ausgesprochen und ein Kursziel von 15 US-Dollar angesetzt. Die Aktienexperten des Börsenbriefes würden sich dem anschließen, zumal das Unternehmen am 14. Mai besser als erwartete Zahlen für das 1. Quartal gemeldet habe. Die Höchststände von Titan hätten bei gut 60 US-Dollar gelegen.

Die Experten von "Global Biotech Investing" sehen bei der Titan-Aktie gute Chancen auf steuerfreie 200% Gewinn in zwei Jahren.

[BonMala]

6/3/2002 TTP Titan Pharmaceuticals Inc

Last: 3.77
-0.18

Legg Mason: Sell

Market Performance Remains cautous about iloperidone`s prospects.....

[BonMala]

Titan kommt in Schwung....
hat jemand Ahnung wieso?

[boriz]

usa:
TTP Last: 3.02 Change: +0.02 +0.67% Volume: 40,200 10:47am ET
7/11/2002

Frankfurt TN7 EUR 3,30 2,80 - 0,500 - 15,15% 7.971 2.683 11. Jul 16:33

was ist da los ?

greetz,
boriz

[BonMala]

der Kursverlauf seit den letzten drei Tagen ist nicht übel

[eueropa]

Hi boriz!

Ich hab die letzten Titans zu 2,80 bekommen!
Sorry about that!
Sind heute schon auf 3,55 (+28%) weiter so!

[boriz]

hi opa

glückwunsch, aber da brauchste dich doch nicht zu entschuldigen..

greetz,
boriz

[Erbse1]

Na das wars dann mit Zomaril.
“Iloperidone has been further investigated regarding its potential for cardiovascular side-effects, specifically prolongation of the QT interval in the electrocardiogram, in patients with schizophrenia. In a recent study, the drug`s potential for QTc prolongation was shown to be similar to that seen with ziprasidone [Geodon]. Based on these results, Novartis and its partner, Titan, will re-evaluate future steps for the project.”
--

[Mr.Arrogance]

sehr schlechte news!
damit ist iloperidone wohl endgültig tot, wie ich früher schon mutmasste. also noch einmal die frage:
was ist TTP wert ohne iloperidone?
lohnt sich ein einstieg und auf welchem niveau?
evtl. bei 2$?

[BonMala]

Dafür, dass TITAN noch so viel in der Pipeline haben soll,
sind sie ganz schön gefallen.

[BBPushi]

Das fortgeschrittenste Medikament in der TITAN Forschung Iloperiodone ist leider nicht besser als ähnliche schon am Markt erhältliche ...
Als kein Wunder, dieser Absturz.
Hoffentlich sind die sieben anderen Produkte besser.
Ich werde weiter beobachten. Bin nicht investiert.
Kursziele wurden im übrigen von DB Securities von 15 $ auf 12 $ und inzwischen 2.4 $ korrigiert ...
Weiß jemand, ob TITAN wirklich noch 100 Mio $ Cash hat. (Dies würde ca. 3.5 $ pro Aktie entsprechen.)

[BBPushi]

Sehr geehrter Herr ...,

vielen Dank für Ihre Anfrage. Die Kooperation mit Titan wird weiter
fortbestehen, der Start einer Studie der Phase IIb steht unmittelbar bevor. Der
von Ihnen erwähnte Neurologe Prof. Poewe ist Mitglied im sogenannten Steering
Committee.

Viele Grüße

Schering AG
Claudia Schmitt

[puhvogel]

Iloperiodone sieht ziemlich tot aus, insofern ist diese Meldung nicht wirklich entscheidend.

U.S. FDA Issues Approvable Letter for ABILIFY(TM)

Potential New Treatment Option for Schizophrenia

PRINCETON, N.J., and TOKYO, Sept. 3 /PRNewswire-FirstCall/ --Bristol-Myers Squibb Company (NYSE: BMY) and Otsuka Pharmaceutical Company,Ltd., have received an approvable letter from the U.S. Food and Drug Administration (FDA) for aripiprazole (proposed tradename ABILIFY(TM)
Tablets), an investigational treatment for schizophrenia. Final approval of aripiprazole is contingent upon the successful completion of ongoing discussions with the FDA. Aripiprazole was discovered by Otsuka Pharmaceuticals.
"The issuance of this letter is a significant milestone for aripiprazole," said Peter R. Dolan, chairman and chief executive officer, Bristol-Myers Squibb. "Bristol-Myers Squibb and Otsuka Pharmaceuticals are working closely together with the FDA towards final approval of aripiprazole."
"Aripiprazole is one of the most exciting and gratifying discoveries made
by Otsuka scientists," said Tatsuo Higuchi, president, Otsuka Pharmaceuticals. "Our commitment to the treatment of mental illness and our partnership with Bristol-Myers Squibb are sources of great pride for us."
Otsuka Pharmaceuticals submitted a New Drug Application (NDA) for aripiprazole in October 2001.

[eueropa]

Wer kauft denn hier 1000 Stück in diesem Marktumfeld !!??

[BonMala]

kann mal jemand was über die Gründe des Chartverlaufs sagen?

[BonMala]

Dieselbe Frage noch einmal.....

[Braini]

11,5% + , warum das ? gibts da news ?

[desastermaster]

Mja, gestern gabs Quartalszahlen
aber die koennen es eigentlich nicht gewesen sein.
Ausser Einsparungen gibts da wenig neues. Immerhin
versuchen sie die Kostenseite in den Griff zu bekommen.
Best
dm

Press Release for Titan Pharmaceuticals Inc


Titan Reports First Quarter 2003 Results
5/15/2003 7:30:00 AM
SOUTH SAN FRANCISCO, Calif., May 15, 2003
/PRNewswire-FirstCall via COMTEX/ -- Titan
Pharmaceuticals, Inc. (TTP) today announced
financial results for the first quarter ended March
31, 2003. Operating results indicate that the
company achieved its targeted strategic reduction
in expenditures for the first quarter of 2003.

Operating expenditures for the first quarter of
2003 were approximately $7.0 million, a 25%
reduction compared with operating expenditures of
$9.4 million for the fourth quarter of 2002. Net
loss for first quarter 2003 was approximately $6.5
million, or $0.24 per share, compared to $5.0
million, or $0.18 per share, for the first quarter
in 2002, with the difference in net loss primarily
due to difference in revenue. Revenues for first
quarter 2003 were approximately $26,000, compared
to $2.3 million for first quarter 2002. The change
in revenue and net loss is the result of a
milestone payment received for Spheramine(R) in the
first quarter 2002.

Interest income, net of other expenses for first
quarter 2003 was approximately $472,000 compared to
$1.4 million for first quarter 2002, primarily
reflecting lower interest rates. At March 31, 2003,
the Company had approximately $66.1 million in
cash, cash equivalents and marketable securities.

"As a result of our strategic focus on four core
product development programs -- Spheramine,
Pivanex(R), gallium maltolate and Probuphine(TM),
we were able to achieve our targeted 25% reduction
in operating expenditures in the first quarter this
year, compared with fourth quarter last year,"
stated Dr. Louis R. Bucalo, Chairman, President and
CEO. "With internal resources directed at these
four programs, and the continued support of our
corporate partner for Spheramine, Schering AG,
Germany, we are making good progress moving these
four products forward in clinical testing."

Titan is advancing the following four
clinical-stage product development programs.

Spheramine

Enrollment in a randomized, controlled, blinded
Phase IIb clinical study of Spheramine in advanced
Parkinson`s disease is proceeding on schedule.
Schering AG, Germany, Titan`s corporate partner for
the development of Spheramine, is funding the
study. In April 2003, new results from a pilot
study of Spheramine, demonstrating an average 41
percent improvement in motor function 24 months
post treatment, were presented at the American
Academy of Neurology.

Pivanex

A randomized Phase IIb clinical study of Pivanex
and docetaxel in non-small cell lung cancer (NSCLC)
is being initiated with patient enrollment planned
to commence in June, following the completion of
the current dose escalation study evaluating the
safety of this treatment combination. In related
development activities, preclinical study results
demonstrating that Pivanex is synergistic with
docetaxel in NSCLC will be presented at the meeting
of the American Association for Cancer Research in
July 2003. Pivanex is a histone deacetylase
inhibitor with demonstrated preliminary evidence of
anti-cancer activity in a previous open label Phase
II study in NSCLC.

Gallium Maltolate

Titan is completing the Phase I portion of a Phase
I/II clinical study of gallium maltolate in several
cancers, and plans to advance gallium maltolate
into Phase II testing in the second half of 2003.
Additional preclinical testing of gallium maltolate
in other disease settings is also ongoing. Gallium
maltolate is a novel oral agent for the treatment
of cancer and bone disease.

Probuphine

Titan`s pilot clinical study of Probuphine is
planned to begin in June. Probuphine is a novel
long-term treatment for opiate addiction, which
utilizes the Company`s proprietary ProNeura drug
delivery system to deliver up to six months of
buprenorphine, an approved treatment for opiate
addiction.

Other Programs

Titan continues to work with corporate partner
Novartis to evaluate strategic options for
iloperidone, including potential sublicensing,
continuing iloperidone development, or returning
product rights to Titan. In addition, the company
is no longer allocating internal resources to the
monoclonal antibodies CeaVac(R), TriAb(R) and
TriGem(TM) as part of its strategic plan to reduce
expenditures.

About Titan Pharmaceuticals

Titan Pharmaceuticals, Inc. is a biopharmaceutical
company focused on the development and
commercialization of novel treatments for central
nervous system disorders, cancer and other serious
and life-threatening diseases. Titan`s numerous
products in development utilize novel technologies
that have the potential to significantly improve
the treatment of these diseases. Titan also
establishes partnerships with multinational
pharmaceutical companies and government
institutions for the development of its products.

The press release may contain "forward-looking
statements" within the meaning of Section 27A of
the Securities Act of 1933 and Section 21E of the
Securities Exchange Act of 1934. Such statements
include, but are not limited to, any statements
relating to the Company`s development program and
any other statements that are not historical facts.
Such statements involve risks and uncertainties,
including, but not limited to, those risks and
uncertainties relating to difficulties or delays in
development, testing, regulatory approval,
production and marketing of the Company`s drug
candidates, unexpected adverse side effects or
inadequate therapeutic efficacy of the Company`s
drug candidates that could slow or prevent product
development or commercialization, the uncertainty
of patent protection for the Company`s intellectual
property or trade secrets and the Company`s ability
to obtain additional financing if necessary. Such
statements are based on management`s current
expectations, but actual results may differ
materially due to various factors, including those
risks and uncertainties mentioned or referred to in
this press release.

SOURCE Titan Pharmaceuticals, Inc.

Copyright (C) 2003 PR Newswire. All rights
reserved.

[Siby]

Hallo,

Große Umsätze!!

Gibts was Neues ?

Gruß

[schachi]

guckst du hier:
http://biz.yahoo.com/djus/030630/1216000758_2.html

[desastermaster]

Ein paar neue vorklinische Daten...
und bei uns tickern sie gleich aus in Amiland dagegen
erstmal keine Reaktion.
Best
dm


Press Release for Titan Pharmaceuticals Inc


Titan Announces Pivanex(R) Increases Anti-Cancer
Activity Combined With Standard Chemotherapy for
Lung Cancer
7/14/2003 8:30:00 AM
New Data Presented at American Association for
Cancer Research

SOUTH SAN FRANCISCO, Calif., Jul 14, 2003
/PRNewswire-FirstCall via COMTEX/ -- Titan
Pharmaceuticals, Inc. (TTP) today announced new
preclinical study results further demonstrating
that Pivanex(R), combined with the approved
chemotherapeutic agent docetaxel, significantly
increased anti-tumor activity in non-small cell
lung cancer (NSCLC) cells. The new data, presented
at the 94th annual meeting of the American
Association for Cancer Research, confirm results of
previous studies that have shown Pivanex
demonstrates significant anti-cancer activity, and
is synergistic in combination with several current
chemotherapy agents.

Pivanex is a broad-spectrum anti-cancer agent that
acts by inhibiting key enzymes called histone
deacetylases, which are responsible for changing
the expression of cancer-related genes. By altering
tumor-specific gene expression, Pivanex slows tumor
growth and causes destruction of cancer cells.
Docetaxel is a chemotherapeutic agent approved for
the treatment of patients with NSCLC who have
previously been treated with chemotherapy.

The combination of Pivanex and docetaxel was
evaluated for anti-cancer activity in two human
NSCLC cells lines (NCI-H522, NCI-H23). The two cell
lines were treated with Pivanex alone, docetaxel
alone, and Pivanex plus docetaxel. Results of the
study showed that Pivanex, combined with docetaxel,
resulted in significantly enhanced tumor cell death
compared to either treatment alone. The synergistic
anti-cancer effects were seen across a range of
doses.

In a previously completed Phase II open-label study
in advanced NSCLC in which Pivanex was administered
as a single agent, Pivanex demonstrated encouraging
tumor response and survival data. For example,
among the 32 Pivanex patients in this study who had
received less than three prior therapies, the
partial response rate was 9.4%, median survival was
7.9 months, and 1-year survival was 31%. These
results are similar to those seen in two docetaxel
pivotal trials in which comparable patient groups
were treated with 75 mg of docetaxel. In those
docetaxel pivotal trials, partial response rates
were 5.5% and 6.7%, median survival was 5.7 months
and 7.5 months, and 1-year survival was 32% and
37%.

Based on the results of previous in-vitro and
in-vivo studies that demonstrated additive or
synergistic effects of combining Pivanex with
docetaxel, Titan initiated a Phase IIb clinical
study of this combination for second-line treatment
of NSCLC. A dose-escalation study of this
combination has successfully been completed and has
shown that Pivanex can safely be administered at
its single-agent dose, and docetaxel at its
approved dose for NSCLC, with the only significant
side effects being those typically associated with
docetaxel treatment.

The ongoing Phase IIb clinical study is a
multicenter, randomized, controlled study that will
enroll 225 patients at more than 50 study sites in
seven countries, and will evaluate the safety and
efficacy of Pivanex plus docetaxel, versus
docetaxel alone.

"Histone deacetylase inhibition is a key area of
cancer research, and Pivanex represents an
important potential advance based upon this novel
mechanism of action," said Mark Green, M.D.,
Professor of Medicine, Division of
Hematology/Oncology, Medical University of South
Carolina and Chair of the Pivanex Phase IIb study.
"The ability to combine Pivanex with current
chemotherapy in the treatment of lung cancer may
potentially provide a new treatment combination,
with a likelihood of minimal additional side
effects. These data, as well as the safety of the
combination in the recently completed dose
escalation study, provide a sound rationale for the
current development of Pivanex in combination with
docetaxel in the treatment of advanced NSCLC."

The American Cancer Society estimates there will be
nearly 172,000 new cases of lung cancer and more
than 157,000 deaths from lung cancer in the United
States this year. Non-small cell lung cancer is the
most common form of the disease, representing 80
percent of all cases.

"We are encouraged by the results of this most
recent study and previous data from preclinical and
clinical testing that support the further
evaluation of Pivanex in the treatment of NSCLC,"
said Dr. Louis R. Bucalo, Chairman, President and
CEO of Titan.

SOURCE Titan Pharmaceuticals, Inc.

Copyright (C) 2003 PR Newswire. All rights
reserved.

[Freudmann]

Titan pharm. (TTP) gehört zu den Aktien, die ich regelmäßig
beobachte und von Zeit zu Zeit in kleineren Mengen hinzukaufe.
Im Zusammenhang mit der Beobachtung stelle ich fest,
daß seit ca. drei Wochen in Frankfurt im Tausender-Bereich aus dem Ask heraus gekauft wird. Es gab Tage, da machte
der Umsatz dieser in den USA beheimateten Gesellschaft
mehr als 10% des USA-Umsatzes aus.
Es gibt doch einen Vertrag von Titan ph. mit Schering.
Könnte es möglich sein, daß einer/einige in D mehr wissen als die Masse der US-Boys. Steht uns hier möglicherweise
eine (erfreuliche) Nachricht bevor? Was denkt ihr?

Schaut Euch den Kurzfristchart an! Kaufsignale wurden generiert. Schaut Euch aber auch den 5-Jahres-Chart an!

MfG

[Freudmann]

[Freudmann]

[Freudmann]

Wenn ihr euch auf der Homepage dieser Firma über die überraschend zahlreichen Entwicklungsprojekte (in ebensoviel unterschiedlichen Entwicklungsstadien) dieser
AG informiert,
werdet ihr meine Tagträume (über das "Heranlaufen" des Kurses an den Widerstand um ca.20$ auf Sicht von etwa 24 Monaten) vielleicht verstehen.
Ihr dürft mich freilich für meine Tagträume auch verbal
steinigen!

MfG

[goldmaki]

Moin Freudmann, wäre ja schön, wenn der Wert so laufen würde, wie die Coeur d`Alene.

Was hat es eigentlich mit dieser Schering-Verbindung auf sich??

Danke und Gruß

goldmaki

[Freudmann]

Die 2,57$ von gestern 8.9.03 sind der seit Mitte Juni d.J.
höchste Kursstand. Die mehrwöchige Schiebezone im Bereich
2,00 bis 2,50$ ist offensichtlich überwunden.

Viele Indikatoren befinden sich im grünen Bereich!

[Erbse1]

Hallo Freudmann, ich kopiere Dir mal ein altes Posting bezüglich der Schering Zusammenarbeit von mir.
Guilford ist mittlerweile gescheitert, also nicht mehr beachten.
Liebe Grüße
Erbse1
-----------------------------------------------------------
Hier also jetzt der Bericht zu Spheramine. Spheramine ist das nächste Medikament, mit dem sich TTP große Hoffnung im Kampf gegen die Parkinsonerkrankung macht.
Erst mal kurz zu Parkinson. Gemessen an der Gesamtbevölkerung sind ca 100 - 200 pro 100000 betroffen. Bei den über 60 jährigen beträgt der Anteil ca 1%.
Bestimmte Nervenzellen bilden sich im Gehirn zurück und hauptsächlich die Botenstoffe Dopamin und Acetylcholin werden nicht mehr im richtigen Maße produziert. Es kommt zum Ausbruch der Krankheit. Verlauf und Schweregrad variieren stark von Patient zu Patient. Es kommt zu Mißempfindungen in Gliedern und Nacken,Müdigkeit, Depression und Zittern. Später treten dann bei manchen Patienten Gang- und Gleichgewichtsstörungen auf.
Bisher gibt es keine Möglichkeit der Erkrankung vorzubeugen oder zu heilen. Doch es gibt ein breites Spektrum an Behandlungsmöglichkeiten die Symptome zu lindern.

Bisher sind mir zwei Lösungsansätze bekannt, Parkinson auch in Zukunft heilen zu können.
Als wohl ernstzunehmendster Konkurrent ist hier Guilford Pharmaceuticals GLFD zu nennen, die hier mit Amgen zusammenarbeiten. Im Tierversuch gelang es die Krankheit nicht nur aufzuhalten, sondern auch umzukehren. Es handelt sich um den Wirkstoff Neuroimmunophilinliganden, bei dem es gelang im Tierversuch 90% der verloren gegangenen Fähigkeiten wieder herzustellen. Der Wirkstoff kann geschädigte Nervenzellen regenerieren ohne Auswirkung auf die gesunden Nevenzellen. Außerdem wird dieser Substanz ein Nervenzellschutz gegen weitere Schädigungen zugeschrieben.
Ich habe Guilford nicht weiter untersucht aber ich denke mal daß auch hier eine besondere Recherche lohnt. Wir könnten ja auf diesem Gebiet dann mit den GLFD Leuten zusammenarbeiten. Dieses Medikament befindet sich unter dem Namen NIL-A seit August 2000 in Testphase2.
Einen ähnlichen Weg beschreitet Titan mit Spheramine. Aus ersten Studien ist belegt, das ein bedeutender Fortschritt bei den Grundsymptomen und bei den motorischen Funktionen erzielt wurde. Die Ergebnisse von Phase1 und Phase2 werden dieses Jahr auf einem wissenschaftlichen Treffen präsentiert. Interessant in diesem Zusammenhang ist noch, das Titan hier auf die patentierte CCM Technologie zurückgreift. CCM ist ein Microträger, der es ermöglicht fehlende oder mangelnde Neurotransmitter zu ersetzen. Als weitere Anwendungsgebiete werden hier Alzheimer, Epelepsie und bestimmte Krebsarten genannt. Durch diese Anwendung werden dann wieder neue Nervenzellen gebildet, die dann die Produktion von den fehlerhaften Neurotransmittern wieder ins Gleichgewicht bringen.
Titan arbeitet bei Spheramine und der CCM Technologie mit Schering AG zusammen. Erfolgshonorare und Beteiligungen aus Verkäufen sind mir leider nicht bekannt. Vielleicht hat ja jemand anders die Daten. So, das wars erstmal in Kurzform zu Spheramine.
Liebe Grüße an alle Erbse1
-----------------------------------------------------------

[Freudmann]

Hallo Erbse1 Danke für dieses Posting in Deinem Thread.
Ich hatte es noch in Erinnerung. Habe aber aus Zeitnot
nicht nachgesehen. Dies ist jetzt erledigt. Danke nochmals!
Damit ist auch die Anfrage von Goldmaki beantwortet.

Wichtig für mich: Wie siehst Du in mittelfristiger Sicht die Chancen bei TTP?
Wenn man sich die Kursentwicklung ansieht, sieht es so aus
als steht der Kurs auf dem Sprung nach oben.
Auffällig die relativ hohen Umsätze an manchen Tagen
aus dem Ask heraus gekauft, aus Deutschland.
Chartmäßig ist alles im "grünen" Bereich.
Ich habe heute bei 2,24E in Frankfurt nachgekauft.
Wie siehst Du die Situation?

[Erbse1]

Hallo Freudman, ich kann Dir leider keine Antwort geben. Nach dem Scheitern von Zomaril und der Zulassung der Konkurrenzprodukte Geodon und Abilify beschäftige ich mich nur noch am Rande mit Titan.
Langfristig könnte sich ein Investment bei Erfolg der Krebsmedikamente lohnen. Doch meine Kenntnisse auf diesem Gebiet reichen für eine Beurteilung nicht aus.
Ich wünsche Dir allerdings viel Glück mit Titan.

Liebe Grüße
Erbse1

[goldmaki]

Danke für die Antwort!

gruß goldmaki

[Freudmann]

Dieser Chart weckt Bedürfnisse bzgl. TTP

[Freudmann]

Titan Announces Results from Study of Gallium Maltolate In Patients with Advanced Paget`s Disease
Monday September 22, 8:30 am ET
Data Presented at 25th Annual Meeting of the American Society For Bone and Mineral Research


SOUTH SAN FRANCISCO, Calif., Sept. 22 /PRNewswire-FirstCall/ -- Titan Pharmaceuticals, Inc. (Amex: TTP - News) today announced favorable results presented at the 25th Annual Meeting of the American Society For Bone and Mineral Research in Minneapolis, Minnesota, with oral gallium maltolate demonstrating the achievement of targeted, potentially therapeutic serum levels of gallium in patients with advanced Paget`s disease.
Paget`s disease of bone is characterized by excessive bone resorption. An estimated 3% of adults in the United States are affected with Paget`s disease. Many patients have significant bony pain and an increased risk of bone fracture.

This clinical trial evaluated the safety of gallium maltolate, and gallium serum levels, after oral administration of one of three doses, 200, 400 or 600 mg, in twelve patients with advanced Paget`s disease of bone or primary hyperparathyroidism. A single daily dose was administered on day one and three consecutive daily doses were administered fourteen days later. Results demonstrated that serum gallium concentrations increased in a linear fashion with increasing doses. A three-fold increase in the oral gallium maltolate dose resulted in a three-fold increase in mean serum gallium levels. Gallium maltolate was well-tolerated and clinically observed adverse events were generally mild.

"The results of this pilot study demonstrate that potentially therapeutic serum levels of gallium can be safely achieved with this oral formulation. This is especially encouraging because even lower serum levels of gallium in other studies have shown activity in Paget`s disease of bone," said Alice B. Gottlieb, M.D., Ph.D., Professor of Medicine at Robert Wood Johnson Medical School and the lead clinical researcher on the trial. "The results support further assessment of gallium maltolate`s effectiveness in Paget`s disease and as an anti-resorptive agent."

Gallium maltolate is a novel, orally active agent being developed by Titan for the treatment of several types of cancers and for bone-related disease.

"We are pleased with the favorable results achieved in this pilot study, providing support for further clinical trials of gallium maltolate in this area," said Dr. Louis R. Bucalo, Chairman, President and CEO of Titan.

Gallium maltolate is designed to protect bone from the effects of increased breakdown due to metabolic disease such as Paget`s and cancer. Previous studies have shown that treatment with intravenous gallium nitrate appears to favorably impact calcium deposition, making bones stronger and more resistant to degradation by cancer metastasis.

[Freudmann]

[Freudmann]

T.A. on TTP
by: windsurfar (36/M)
Long-Term Sentiment: Buy 09/23/03 11:25 pm


Highest close in 10 days, support at 2.40 has been holding, time to move to $3, IMO.
Will be more news soon, time to hold or buy, not to sell.

[mamers]

Titan Announces Positive Preliminary Results for Probuphine(TM) in the Treatment of Opiate Addiction

SOUTH SAN FRANCISCO, Calif., Sep 26, 2003 /PRNewswire-FirstCall via COMTEX/ --
Titan Pharmaceuticals, Inc. (Amex: TTP) today announced positive interim results
for the first cohort of patients in a pilot clinical study evaluating the safety
and efficacy of Probuphine, Titan`s novel, proprietary product in development
for the treatment of opiate addiction. Preliminary data, presented today at the
International Society of Addiction Medicine in Amsterdam, demonstrate that all
six patients treated with Probuphine at the first dose level have been safely
switched from daily sublingual buprenorphine therapy to Probuphine, with
maintenance of therapeutic benefit and no significant adverse events.

Probuphine is a novel product in development by Titan that is designed to
deliver buprenorphine continuously for up to six months following a single visit
to the doctor`s office. Continuous long-term delivery of buprenorphine may
eliminate many challenges associated with daily oral therapy, including poor
compliance, variable blood levels, risk of misuse, morning withdrawal symptoms
before each dose, and overall reduced therapeutic value. Probuphine utilizes
Titan`s proprietary drug delivery system, which incorporates an ethylene vinyl
acetate (EVA) copolymer that forms a matrix in combination with buprenorphine.
The EVA/buprenorphine matrix is then made into a small, flat rod that is placed
under the skin. Studies to date indicate that Probuphine allows consistent drug
levels to be maintained in the blood, avoiding the peak and trough levels seen
with oral dosing.

Orally administered buprenorphine was approved in the U.S. for the treatment of
opiate addiction in late 2002, and is beginning to emerge as a preferred agent
for the treatment of this condition. In France, where oral buprenorphine has
been approved for several years, approximately 50% of individuals with opiate
addiction are under treatment with buprenorphine, with annual sales of
approximately US$ 80 million in 2002. In the U.S. it is estimated that there are
approximately 1.3 million people afflicted with opiate addiction. In addition,
there are over 1 million people addicted to prescription painkillers,
representing an additional potential market for drugs such as Probuphine.

The open label pilot clinical study will evaluate three dose levels of
Probuphine. The study, initiated in June 2003, will enroll a total of up to 18
opiate-dependent patients, who will be switched from daily sublingual
buprenorphine to Probuphine. The first six patients, who were taking 8 mg. of
buprenorphine daily, have been switched to Probuphine, and have not displayed
any significant signs of withdrawal or craving. In addition, the patients have
not reported opiate abuse and no illicit opioids have been detected in patient
testing. Pharmacokinetic data show steady state serum buprenorphine
concentrations in the targeted therapeutic range.

"These preliminary results suggest that patients with opiate addiction can be
safely switched from buprenorphine to Probuphine with maintenance of therapeutic
effect," said Jason White, Ph.D., Professor, Department of Clinical and
Experimental Pharmacology, University of Adelaide, Australia and lead clinical
investigator for the study. "The ease of use associated with Probuphine may help
overcome the challenges of daily dosing, and potentially provides many patients
with a more effective treatment option."

"These interim results support Probuphine`s potential as a preferred maintenance
therapy for opiate addiction with important potential advantages to current
treatments," said Louis R. Bucalo, M.D., Chairman, President and CEO of Titan.

The pilot clinical study is now treating the second cohort of six patients, who
will be switched from 16 mg. of daily sublingual buprenorphine treatment to
Probuphine. The study is expected to be completed by the second half of 2004.

About Titan Pharmaceuticals

Titan Pharmaceuticals, Inc. (Amex: TTP) is a biopharmaceutical company focused
on the development and commercialization of novel treatments for central nervous
system disorders, cancer and other serious and life- threatening diseases.
Titan`s products in development utilize novel technologies that have the
potential to significantly improve the treatment of these diseases. Titan also
establishes partnerships with multinational pharmaceutical companies and
government institutions for the development of its products.

The press release may contain "forward-looking statements" within the meaning of
Section 27A of the Securities Act of 1933 and Section 21E of the Securities
Exchange Act of 1934. Such statements include, but are not limited to, any
statements relating to the Company`s development program and any other
statements that are not historical facts. Such statements involve risks and
uncertainties, including, but not limited to, those risks and uncertainties
relating to difficulties or delays in development, testing, regulatory approval,
production and marketing of the Company`s drug candidates, unexpected adverse
side effects or inadequate therapeutic efficacy of the Company`s drug candidates
that could slow or prevent product development or commercialization, the
uncertainty of patent protection for the Company`s intellectual property or
trade secrets and the Company`s ability to obtain additional financing if
necessary. Such statements are based on management`s current expectations, but
actual results may differ materially due to various factors, including those
risks and uncertainties mentioned or referred to in this press release.

SOURCE Titan Pharmaceuticals, Inc.

[Freudmann]

Seit 13 Tagen in enger Bandbreite zwischen 2,40 und 2,50 $.
Heute immerhin mit 2,50 $ 15-Tage-Hoch.

Die Entscheidung, ob nachhaltig nach oben oder wieder
runter, naht!

Warten wir es ab.!

[goldmaki]

WISO-Tipp
Gold ist nur für solche Anleger geeignet, die ein globales Krisenszenario befürchten. Dabei hat es sich bisher stets als wertbeständigste Anlageform erwiesen. Wer sich lediglich gegen Inflation absichern möchte, für den gibt es bessere Anlageformen.

[Freudmann]

goldmaki,
wie Recht Du hast!
Oder meinst Du das ironisch? Ich bin mir nicht ganz sicher!

Wie auch immer: Auch wenn man sich goldmaki nennt,
scheint die Richtung der Entwicklung bei TTP zumindest kurzfristig klar zu sein: Aufwärts! Nordwärts! Gewinnbringend!

[Freudmann]

Es ist schon atemberaubend zu sehen, wie TTP nach 17-tägigen Kursen (bei rel. niedrigen Umsätzen) im engen Bereich von 2,40 - 2,50 $ innerhalb von zwei Tagen mit
massiver Gewalt (bzgl. Umsätzen) und Kursveränderungen
ausbricht. Auch heute wieder hoher Umsatz und Kurssteigerung auf 2.94$ (+8,09%).
Ich denke, die positiven Nachrichten werden noch folgen,
der Kurs läuft schon mal voraus!

Chart in # 92 ansehen!

[Freudmann]

TTP aktuell 3.04 $ (+11,76%)
bisher mehr als der fünfache Umsatz!
Wann kommt die Nachricht?

[Freudmann]

Der Vorschlag eines Amis aus dem Yahoo-Board über TTP:

DO NOT WAIT FOR NEXT NEWS TO BUY

IT MUST BE GOOD AND SOMEONE MUST KNOW ABOUT IT.

[Freudmann]

Hier der aktuelle Mix von 13 Indikatoren zu TTP in
verschiedenen Zeitbereichen.


http://quotes.barchart.com/texpert.asp?sym=ttp

[Freudmann]

Eine lehrbuchreife Situation einer im kräftigen Aufwind
befindlichen Aktie!

Man beachte besonders Moving Average, RSI, Volumen und
MACD in den unterschiedlichen Zeitabständen.

http://quotes.barchart.com/techrept.asp?sym=TTP

[Freudmann]

Nach zwei Tagen der Konsolidierung ging es gestern
und geht es heute bei lebhaftem Umsatz weiter (für mich nicht überraschend) nordwärts!
Aktuell 3,21 $ (+6,2%)
Zur Information der chartmäßigen Situation die in diesem
Thread vorhandenen aktuellen Charts und Links ggf. aufrufen!

[Freudmann]

fascinating day



Today...
Seattle genetics -2.4%
DNA -1.8%
Gern -8.4%
OXGN -1.9%
biotech index down 2.15%

TITAN UP 6.6% interesting move against the group, something is coming.

[Erbse1]

Titan erweitert Produktpalette

Titan Acquires Novel Agent in Clinical Testing for The Treatment of Congestive Heart Failure
http://biz.yahoo.com/prnews/031016/nyth071_1.html
Viel Glück
Erbse1

[Freudmann]

Vielen Dank Erbse1 (einer der aktivsten "Alt-Titanisten") für die Information, die nachfolgend zu lesen ist.

Es ist also wieder einmal so: erst steigt der Kurs und erst dann kommt die Nachricht! Diese Nachricht beflügelt den heutigen Kursanstieg.

Es sind im Yahoo-Board Meinungen geäußert worden, die
Titan pharm. als die unterbewertestste Aktie (unter Beachtung der Pipline dieser Firma) des gesamten Marktes halten . Diese Meinung haben nicht alle. Wie ist es sonst zu verstehen, daß ich gestern nochmals für 2,35 E
in Ffm. nachlegen konnte. Vielen Dank diesem unbekannten
(unfreiwilligen) Spender!

Press Release Source: Titan Pharmaceuticals, Inc.


Titan Acquires Novel Agent in Clinical Testing for The Treatment of Congestive Heart Failure
Thursday October 16, 8:33 am ET


SOUTH SAN FRANCISCO, Calif., Oct. 16 /PRNewswire-FirstCall/ -- Titan Pharmaceuticals, Inc. (ASE: TTP) announced today that it has acquired a novel product in clinical testing for the treatment of congestive heart failure. The product in development, 3,5-diiodothyropropionic acid, is an orally active analogue of thyroid hormone that has demonstrated in preclinical and clinical studies to date the ability to improve cardiac function, with no significant adverse effects. Beneficial effects demonstrated in these studies include improved cardiac output, as well as improvement in measures of diastolic function. In addition, 3,5-diiodothyropropionic acid, or DITPA, has also demonstrated significant cholesterol and triglyceride lowering capability in pilot clinical testing.
ADVERTISEMENT


Titan plans to develop DITPA as a potential treatment for congestive heart failure (CHF), and also will evaluate its potential use as a treatment for patients with significantly elevated cholesterol and triglyceride levels.

DITPA has completed Phase I and preliminary controlled Phase II testing, and will begin a randomized, double blind Phase II clinical study in patients with CHF in the next few months. This multicenter study is funded by a $3.8 million government grant from the federal Veterans Administration (VA) system.

Congestive heart failure (CHF) is a syndrome of progressive decrease in cardiac function and inability of the heart to pump sufficient blood for proper function of the lungs, kidneys, and other vital organs and tissues. Symptoms include decreasing activity capacity, shortness of breath, and peripheral and pulmonary edema. There are a total of approximately 9 million people in the U.S. and Europe with CHF. In the U.S., approximately 30% of patients have moderate or severe symptoms (New York Hospital Association Class III or IV), and CHF is the most common hospital discharge diagnosis in the U.S. for patients over 65. Currently, only approximately 50% of patients diagnosed with CHF survive for five years, and only 50% of patients with class IV CHF survive one year. New treatments for CHF are greatly needed to improve symptoms, enhance cardiac function, and avoid dangerous and progressive complications of congestive heart failure.

Current treatments for congestive heart failure include angiostensin converting enzyme (ACE) inhibitors and diuretics that act to reduce fluid volume load, and beta-blockers.

DITPA represents a potential new class of agents for CHF, based upon the central role of thyroid hormone in regulating cardiovascular function.

Scientists have previously recognized the important cardiovascular actions of thyroid hormone and its potential beneficial effects on the heart and peripheral blood vessels. In fact, thyroid hormone itself is currently used in the acute post-surgical hospital setting to support the heart after cardiopulmonary bypass in heart surgery patients.

Thyroid hormone is known to have numerous effects on the heart and blood vessels, including decreasing arterial and venous resistance, increasing venous return to the heart, and increasing the effectiveness of cardiac contraction. Collectively, these actions are believed to be potentially beneficial in patients with CHF. Thyroid hormone itself, however, also


significantly increases heart rate, and this effect is undesirable in patients
with CHF.

DITPA is a thyroid hormone analogue that was synthesized and selected based upon its ability to significantly improve cardiac function in experimental models of heart failure without significantly increasing heart rate. Specifically, when DITPA was administered alone or in combination with captopril in animal models of heart failure, cardiac output was improved and left ventricular end diastolic pressure was decreased, without significantly increasing heart rate. In addition, DITPA improved the time for ventricular relaxation, indicating a beneficial effect on diastolic function. (1)

DITPA has demonstrated similar potentially beneficial effects in preliminary human testing. A double-blind, placebo controlled Phase II study in 19 patients with moderately severe (NYHA Class II-III) heart failure demonstrated a significant improvement in cardiac index, a significant decrease in systemic vascular resistance, and no significant increase in heart rate. These study results also supported a beneficial effect of DITPA on diastolic function. (2) In addition, results from this study as well as previous preclinical testing suggest that DITPA is compatible with other current treatments such as ACE inhibitors.

In addition to the above positive effects on cardiovascular function, patients receiving DITPA in this study also demonstrated an approximate 24% reduction in serum cholesterol, as well as a 35% reduction in triglycerides over the course of the 4 week study. Given that coronary artery disease is a major cause of congestive heart failure, the Company believes this lipid lowering activity may be a useful and novel property of DITPA in the treatment of CHF. This property may also be useful in the treatment of patients with isolated significant hyperlipidemia.

Based upon the favorable initial results of clinical testing, DITPA has received a $3.8 MM grant from the Department of Veterans Affairs Cooperative Studies Program to fund a 150 patient, double blind, placebo controlled Phase II study in patients with moderately severe CHF, which is scheduled to commence in Q1 2004.

Titan acquired DITPA through the acquisition of Developmental Therapeutics, Inc. (DTI), a private company established to develop DITPA, and the exclusive licensee of recently issued U.S. and pending international patent applications covering DITPA. Titan acquired DTI in an all stock transaction for 1,187,500 shares of Titan common stock, and made a cash payment of $171,250 to the licensor of the technology. An additional payment of 750,000 shares of Titan common stock will also be made upon the achievement of positive pivotal study results or certain other similar substantial milestones.

"We are very pleased to acquire this novel agent in development for congestive heart failure," stated Dr. Louis R. Bucalo, Chairman, President and CEO of Titan. "DITPA represents a potentially new approach to treatment with a novel mechanism of action."

An expert advisory group has been established to help guide the further development of DITPA, including Dr. Jay Cohn, Professor of Medicine, Cardiovascular Division, Department of Medicine at the University of Minnesota; Dr. Milton Packer, Dickinson W. Richards Jr. Professor of Medicine, Professor of Pharmacology, Chief of the Division of Circulatory Physiology at Columbia University, College of Physicians and Surgeons and Director of the Heart Failure Center at the Columbia-Presbyterian Medical Center in New York City; Dr. Paul Ladenson, Professor of Medicine, Director of the Division of Endocrinology & Metabolism at John Hopkins School of Medicine; Dr. Eugene Morkin, C. Leonard Pfeiffer Professor of Medicine, Co-Director Sarver Heart Center, University of Arizona Health and Sciences Center; and Dr. Steven Goldman, Professor of Medicine and Surgery, Chief of Cardiology, Southern Arizona VA Healthcare System.

"DITPA represents a potentially significant advance in the treatment of congestive heart failure because of its broad spectrum of activity on the heart and peripheral vasculature," stated Dr. Eugene Morkin, C. Leonard Pfeiffer Professor of Medicine, and Co-Director, Sarver Heart Center, University of Arizona Health and Sciences Center. "The ability of DITPA to potentially improve cardiac output without increasing heart rate is very


promising. This unique physiological mechanism of action places DITPA in a new
class of therapy for the treatment of this disease."

[Freudmann]

[Freudmann]

Chart-Bilder vermögen oft mehr als Tausend Worte!

1. 3-Monats-Vergleich zu Biotech-Index BTK:

[Freudmann]

2. 6-Monats-Vergleich zu BTK:

[Freudmann]

3. 1-Jahres-Vergleich zu BTK:

[Freudmann]

4. 2-Jahres-Vergleich zu BTK:

[Freudmann]

Folgt man dem Grundsatz: Der Trend ist Dein Freund, so kann
es unter Beachtung der Vergleichscharts 1-3 auf der einen
und Vergleichschart 4 (s.Unten) auf der anderen Seite
esinnvoll sein in die
wahrscheinlich kurze Konsolidierungsphase in den nächsten
Tagen zu kaufen oder nachzukaufen.

Chance und Risiken jeweils auf eigene Rechnung!

Aktueller Kurs: 3.70 $ (+14%) bei zehnfachem Umsatz!

Die Repräsentationen stehen erst noch an!!!

[Freudmann]

Der Weg nach oben ist frei!!!

[Freudmann]

Von 2,02 E auf 3,48 E - und das Ganze in nur 10 Tagen bei beachtlichem Umsatz - läßt auf eine prinzipielle Neubewertung von TTP schließen.

Letzter Kauf in Ffm 5000 Stck. zu 3,48 E.

[mamers]

ja mei - kaum ist man mal ne woche weg und schon tut sich was *freu* - trau ja meinen Augen kaum!

so kann es bitteschön weitergehen

[Freudmann]

TITAN AT CONFERENCE TUESDAY




Just got confirmation from Titan, they are presnting at Rodman and Renshaw conference in Boston on Oct 21 at 3:20 pm, i believe you can hear a live webcast from the Rodman and renshaw site. Wish they would do a press release on these conferences like other biotachs do. Cant complain though, this new drug has some real potential, 2004 will be the Revival of TITAN.

PS I wouldnt sell a share before this conference presentation.

[Freudmann]

Titans neuer Star ist DITPA!!

Darüber ist in #106 nachzulesen!
Diese Meldung wird ausgesprochen positiv bewertet!
Und morgen nun die Repräsentation!

Ich meine: Die Zeit läuft ab in Ffm unter 3,00 E an diese Aktie zu kommen.

Der Verkäufer heute, der seine Stücke für 2,80 E verkauft
hat, war nicht sehr gut beraten (m.E.) dies zu tun!

In den US-Boards werden Hochrechnungen angestellt bzgl.
des AktienKurses von TTP unter Langfrist-Aspekten, die zu
schreiben ich mir gar nicht traue!

MfG

[Freudmann]

Geht es heute wieder: Aufwärts! Nordwärts! Gewinnbringend! Ich meine: ja!

[Freudmann]

Aktuelle Kandidaten von TTP - noch ohne DITPA:

[desastermaster]

Mja, Ilodoperidon kann man aber erstmal getrost streichen nachdem die nebenwirkungen auf den herzrhythmus doch staerker als erwartet waren und novartis das ding damit scheinbar aufgegeben hat ohne sich schlussendlich darueber zu aeussern.
Best
dm

[Freudmann]

#120
Es mag sein, daß Iloperidone nicht zur Marktreife geführt werden kann. Wäre das mit all diesen Kandidaten möglich, stünde der Kurs von TTP über 100 $. Wir aber halten bei
3,38 $.
Ich meine, die aktuelle Situation sieht gut aus.

- Heute die Repräsentation!

- 3.38>3.35>2.79>2.53>2.42>2.03$

Diese Zahlen bedeuten:
akt.Kurs>5d>20d>50d>100d>200dMA

Weiterhin: der Mix aus 13 Indikatoren ergibt: 96% buy!

Nochmals die Bilanz derletzten 5 Tage:

+3,07 + 6,62 +14,91 -6,76 -2,03$ (gestern)

Die Rückgänge der letzten 2 Tage bei rel geringem Umsatz sind nichts anders als Gewinnrealisierungen.

[Freudmann]

Pardon, letzte Zahlenreihe muß % heissen, nicht $!

[Freudmann]

ttp analysis

Long-Term Sentiment: Strong Buy 10/22/03 05:30 am


let me do some analysis on ttp. i compared the biotechs with mark. cap < 150 mio. and ttp is the best, because :

1a) ttp researches areas with huge market potential (no diagnostics, real medicaments)
1b) pipeline looks impressive
2) cash with 60 mio is very high; cash burn rate is alright
3) recent insider transaction were purchases (this is a very important point)
4) with 72 employes (before the ditpa deal) ttp is not too small; after ditpa even bigger
5) the ceo still holds 350,000 shares. other board members are also holding stocks
6) the ditpa deal shows me that Developmental Therapeutics, Inc. (DTI) has confidence in ttp
7) the stock option deal (1mio for Developmental Therapeutics, Inc. (DTI)) shows me that ttp has confidence in ditpa
8) technical chart analyisis looks good (straight upward trend; free at 4$)
9) at 5$ funds can get in

but remember: if all research fails...forget about ttp

[Freudmann]

TTP strebt weiter aufwärts!
Aktuell 3,72 $ (+4,8%); BTK aber nur +0,04%!

Übrigens hat TTP auf Basis von 4-Wochen eine bessere Performance als 95% !!! aller Biotechs!
Das ist Realität und stammt aus sicherer Quelle!

[goldmaki]

Bären- oder Bullenfalle.....

Das ist hier die Frage. Bollinger-Bänder nach unten durchbrochen...

gruß goldmaki

[Freudmann]

@goldmaki

Nach den Bollinger-Banden nimmt TTP aktuell eine neutrale Position ein.
Im Falle von TTP haben Kauf- und Verkaufentscheidungen,
die nach diesem Indikator ausgerichtet waren, zu einem
eindeutig negativen Ergebnis geführt.
Für andere Aktien mag das wiederrum anders aussehen, vielleicht.
Wichtiger scheinen mir folgende Zahlen:

TTP

........24.10....31.10.
Kurs...3.49....3.29
5-MA...3.49....3.29!
20-MA..3.01....3.21
50-MA..2.63....2.74
100-MA.2.47....2.52
200-MA.2.07....2.11

Es gibt keinen Grund nervös zu werden!
Der 13-Indikatoren-Mix signalisiert: 48%-buy!

Mfg

[Freudmann]

TTP: Sie lebt noch, stirbt nicht!

Und wie sie - die Aktie - lebt.
Bei schwächelndem Biotech-Markt +5,5% auf 3.47 $.

[mamers]

naja - tolle wurst...

Milberg Weiss Files Class Action Suit against Titan Pharmaceuticals, Inc.

SAN DIEGO, Nov 4, 2003 (BUSINESS WIRE) -- Milberg Weiss
(http://www.milberg.com/cases/titan/)" target="_blank" rel="nofollow ugc noopener">http://www.milberg.com/cases/titan/) today announced that a class action has
been commenced in the United States District Court for the Northern District of
California on behalf of purchasers of Titan Pharmaceuticals, Inc. ("Titan
Pharmaceuticals") (AMEX: TTP) common stock during the period between December 1,
1999 and July 22, 2002 (the "Class Period").

If you wish to serve as lead plaintiff, you must move the Court no later than 60
days from today. If you wish to discuss this action or have any questions
concerning this notice or your rights or interests, please contact plaintiff`s
counsel, William Lerach or Darren Robbins of Milberg Weiss at 800/449-4900 or
via e-mail at [e-mail]. If you are a member of this class, you can view a
copy of the complaint as filed or join this class action online at
http://www.milberg.com/cases/titan/." target="_blank" rel="nofollow ugc noopener">http://www.milberg.com/cases/titan/. Any member of the purported class may move
the Court to serve as lead plaintiff through counsel of their choice, or may
choose to do nothing and remain an absent class member.

The complaint charges Titan Pharmaceuticals and certain of its officers and
directors with violations of the Securities Exchange Act of 1934. During the
Class Period, Titan Pharmaceuticals sought to develop Iloperidone (Zomaril), a
potential new drug for the treatment of schizophrenia. The complaint alleges
that from the very beginning of the Class Period, defendants declared that the
development program for Iloperidone was making steady progress through Phase III
clinical trials and towards drug approval in the U.S. Defendants expressed
excitement over the safety and efficacy of Iloperidone and with the Phase III
study results, particularly the statistically significant reduction in the
symptoms of schizophrenia in patients. Defendants concluded that the positive
late-stage development results pointed to an important role for Iloperidone as
an important new option for the treatment of schizophrenia.

Heightened expectations for the success of Iloperidone stood in contrast to an
ongoing process of U.S. Food and Drug Administration review of serious
unaddressed safety issues facing older, established antipsychotic drugs. This
process has resulted in the imposition of severe marketing restrictions for a
number of established antipsychotic drugs. However, during the Class Period,
defendants artificially inflated the price of Titan Pharmaceuticals shares by
issuing a series of materially false and misleading statements about the
Company`s Investigational New Drug and New Drug Applications for Iloperidone
(Zomaril).

As a result of the defendants` alleged false statements, Titan Pharmaceuticals
stock traded at inflated prices during the Class Period, causing millions of
dollars of damages to the Class. However, based on the disclosures made in
defendants` press release of July 22, 2002, pointing to the ability of
Iloperidone to prolong the QT interval and raising serious questions about
Iloperidone cardiovascular safety and marketability, the price of Titan
Pharmaceuticals` shares fell a precipitous 58%, to $1.63, its lowest level ever,
on volume of 3.8 million shares.

Plaintiff seeks to recover damages on behalf of all purchasers of Titan
Pharmaceuticals common stock during the Class Period (the "Class"). The
plaintiff is represented by Milberg Weiss Bershad Hynes & Lerach LLP, who has
expertise in prosecuting investor class actions and extensive experience in
actions involving financial fraud.

Milberg Weiss Bershad Hynes & Lerach LLP, a 190-lawyer firm with offices in New
York, San Diego, San Francisco, Los Angeles, Boca Raton, Seattle and
Philadelphia, is active in major litigations pending in federal and state courts
throughout the United States. Milberg Weiss has taken a leading role in many
important actions on behalf of defrauded investors, consumers, and companies, as
well as victims of World War II and other human rights violations, and has been
responsible for more than $30 billion in aggregate recoveries. The Milberg Weiss
website (http://www.milberg.com) has more information about the firm.

SOURCE: Milberg Weiss

[goldmaki]

@ 126

Danke!

gruß goldmaki, z.Zt. auch in vertex investiert...

[eueropa]

Wie sieht ihr die Klageschrift wegen Betruges? Kann da was dran sein? Gibt es wieder so einen Kurssturz von >50% ? Habe auch noch eine Menge Titan rumliegen!

[Erbse1]

Hallo eueropa. Kann schon sein, daß die Kläger Recht bekommen. Bis zur letzten Veröffentlichung der Testphase 3 war von keinen gravierenden Nebenwirkungen die Rede. Es ist kaum anzunehemen, daß vorher kein EKG gemacht wurde und die Verlängerung des QT Intervalls unbekannt war.
Dies auch noch unter dem Gesichtspunkt, daß das damalige Konkurrenzprodukt Ziprasidone gerade wegen diesem Punkt "nachsitzen" mußte. Ich kann mir schon vorstellen, daß die Kläger große Chancen haben. Aber vor Gericht weiß man ja nie.
Liebe Grüße
Erbse1

[Erbse1]

Hab mal in alten Threads von mir gestöbert. Hier ein Ausschnitt aus einer älteren Meldung zu Zomaril. Noch hier wurde von einem besseren Nebenwirkungsprofil gegenüber der Konkurenz gesprochen. Ich denke mal, daß zu diesem Zeitpunkt schon die Nebenwirkungen bekannt waren. Sieht nicht so gut aus für Titan.
Diese Meldung wurde am 25.03.01 von Titan veröffentlicht.

<The Zomaril(TM) Phase III program in schizophrenia is on schedule for completion very shortly, and we expect filing of the NDA in the second half of this year. Two of the Phase III efficacy studies, as well as additional studies in the elderly and safety studies, are already complete. Preliminary results from these studies suggest that Zomaril may offer significant advantages to patients with schizophrenia and other psychotic disorders by providing efficacy against the symptoms of the disease, while offering an improved tolerability and safety profile when compared with current market leading agents. These preliminary Phase III results are quite exciting, and, in view of the fact that Zomaril addresses one of the largest and fastest growing markets in the pharmaceutical industry, we believe that Zomaril is potentially an enormous pharmaceutical asset. Titan`s corporate partner for development and commercialization of Zomaril, Novartis Pharma AG, is fully funding the Phase III program and is also developing a depot formulation which is in Phase II clinical testing." >

Eine Meldung damals zu Ziprasidone

<Noch 1998 wurde Pfizer die Zulassung des Medikaments Ziprasidone nicht gestattet. Testergebnisse haben bewiesen, dass die Einnahme der Arznei bei Patienten zu potenziell tödlichen Herz-Rhythmus-Störungen geführt hat. Dieser Mangel ist zwar nicht behoben, aber die FDA hat entschieden, dass die Effektivität des Medikaments die Risiken deutlich überwiegt. >


Hab mir damals auch ne blutige Nase geholt.
Liebe Grüße
Erbse1

[Erbse1]

Titan Announces Pivanex(R) Is Active Against Cancer-Related Genes
http://biz.yahoo.com/prnews/031118/nytu110_1.html

[Freudmann]

Geht es bei TTP wieder aufwärts, nach dieser häßlichen Klage?
Ich denke eher ja, als nein!
Wenn ich nicht bis zur Halskrause investiert wäre, würde ich jetzt nachkaufen!

Aktuelle Tages-, Wochen- und Vergleichscharts unter
#118,
#113,
#109 und
#108 ansehen!

Mfg Freudmann, der sich bald über TTP wieder freuen will!

[Freudmann]

Zum vierten Mal seit Anfang November
erreichte TTP die 3$-Marke.
Dreimal prallte die Aktie an diesem Widerstand
ab. Wie wird es weitergehen?

Die aktuelle Chartsituation ist durch Aufsuchen der
im vorigen Posting genannten # gut erkennbar!

MfG Freudmann, der weiter an TTP glaubt!

PS: Übrigens auf 3-Monatssicht zeigt TTP eine um ca.
25% bessere Performance als der Biotech-Index!

[Freudmann]

Na` wer sagts denn!
Heute vormittag war ich nur verhalten optimistisch ob der
Widerstand bei 3 $ überwunden werden kann.
Er kann!
Derzeit bei lebhaftem Umsatz TTP bei 3,21 $ (+7%).

MfG Freudmann, der sich wieder freut!

[Freudmann]

12% im Plus, bei nur verhaltenem NBI, läßt
Hoffnung auf positive news aufkommen, die es noch nicht gibt. Schlußkurs 3.36 $ bei verdoppeltem Umsatz (Vergleich zu gestern)

[Freudmann]

[Freudmann]

TTP ab heute mit MACD-Kaufsignal (s.Chart unter # 118);
-auch Wochenschart unter #113 sowie
-Vergleichschart zu BTK (s.#108) sind interessant.

Auch instutitionelle Anleger kaufen! In den letzten Tagen
aus dieser Gruppe keine Verkäufe!

MfG Freudmann

[Freudmann]

Eben bei Yahoo "aufgelesen":

2004 year of TTP


Results we will get in 2004

DITPA phase II
Pivanex(lung) Phase II
Pivanex (leukemia) Phase I...looking at remission rate
Proneura...Addiction results
Parkinsons proneura testing by NIH (possible by end of year)
Gallium...Phase I results should start coming in on different applications, MM, bladder CA, bone mets
??? ceaVac-triab trials by NCI?? where are they? Possible surprise???
My favorite speculaton is that Pivanex in lung CA will have a significant improvement in Tumor response rate and stable disease...with conversion to Phase III this year!
My second favorite speculation is licensing of Proneaura sub cut delivery system to a major Pharma for its own uses( this would be HUGE)
Good luck in 2004, i think this time in 2005 we will all be very happy with TTP.

[Freudmann]

Durch den gestrigen Kurssprung bei TTP auf 3.15$ (+6,4%)
hat sich natürlich die chartmäßige Situation deutlich
verbessert.
Von 13 Indikatoren signalisieren 7 buy, 5 hold und nur 1
Indikator sell. Insgesamt ergibt das 48% buy.
Zum Vergleich: 1 Woche zuvor: 32% buy.

Der Kurs befindet sich oberhalb aller MA-Werte!
MA 5, 20, 50, 100 und 200:
3.00,3.01,3.01(!),2.79 und 2.42

Zu den Entwicklungskandidaten s.#119!
Chart, daily: #118

Müßig zu sagen, ich bin für TTP 2004 sehr optimistisch!
Zwischen 4.50 und 8 $ liegt mein Erwartungsbereich!
Auf amerikanischen Boards sind auch schon 20 $ (mit Begründung) genannt worden!

Schaun` mer mal!

MfG

[Freudmann]

Bin etwas irritiert, wegen des Rückganges von TTP
gestern auf 2.90$ bei hohen Umsätzen.
Eine Rücksprache eines US-Aktionärs mit der Firmenleitung
soll ergeben haben, daß derzeit keine aktuellen news,
also auch keine schlechten Nachrichten anstehen.
Bei 2.90 $ findet sich ein starker Widerstand!
Dennoch: TTP erscheint mir aussichtsreich und ist aber leider sehr valotil.
Ärgerlich: TTP ist unter die 20- und 50-day-MA Linie
gerutscht. Hat sich aber dennoch deutlich besser als der NBI entwickelt (s.#113).

[Freudmann]

Seit drei Tagen "läuft" TTP überraschend gut!
16% Plus, aber nur 2% Plus NASDAQ auf Sicht von 5 Tagen.
Heute bei negativem BTK und auch NBI Steigerung bei TTP auf
3.37$ (+4,7%)!

[Freudmann]

Per Zufall habe ich eine schon etwas länger zurückliegende Einschätzung von "Deutsche Securitas"
gefunden übrt TTP:
Titan Pharmaceuticals "strong buy"
Deutsche Securities

Rating-Update:

Die Analysten vom Investmenthaus Deutsche Securities stufen die Aktie von Titan Pharmaceuticals (WKN 914404) unverändert mit "strong buy" ein. Obwohl das Unternehmen über sieben Präparate in unterschiedlichen klinischen Testphasen verfüge, betrage die Marktkapitalisierung nur rund 120 Millionen US-Dollar. Das Kursziel sehe man bei 15 US-Dollar.

[Freudmann]

Vorbörslich TTP 3,85$ !!!!

[Freudmann]

Wie schnell es doch gehen kann:
Am Do. verg.Woche hielten wir noch bei
2.88$, jetzt stehen wir bei 3.66 $ (+27% Plus).
Das 52-Wo-Hoch ist in greifbare Nähe gerückt!
Die beste Zeit kommt aber noch für TTP!
Meine Aktien werde ich mindest bis Jahresende unbedingt halten!

MfG Freudmann, der nicht unzufrieden ist!